CN110430892A - 肉毒神经毒素在治疗流涎中的改进的用途 - Google Patents

肉毒神经毒素在治疗流涎中的改进的用途 Download PDF

Info

Publication number
CN110430892A
CN110430892A CN201880012061.6A CN201880012061A CN110430892A CN 110430892 A CN110430892 A CN 110430892A CN 201880012061 A CN201880012061 A CN 201880012061A CN 110430892 A CN110430892 A CN 110430892A
Authority
CN
China
Prior art keywords
asn
ile
leu
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880012061.6A
Other languages
English (en)
Inventor
J·西科斯
I·普莱特
M·阿尔图斯
M·克鲁尔
N·韦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharmaceuticals
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharmaceuticals filed Critical Merz Pharmaceuticals
Publication of CN110430892A publication Critical patent/CN110430892A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明涉及肉毒神经毒素在治疗流涎或与唾液产生增多有关的疾病或病状中的改进的用途。具体地是公开肉毒神经毒素,所述肉毒神经毒素以介于1.45:1与1.7:1之间的剂量比率施用到腮腺和颌下腺中。

Description

肉毒神经毒素在治疗流涎中的改进的用途
技术领域
本发明涉及肉毒神经毒素在治疗与流涎或唾液产生增多相关的疾病或病状中的改进的用途。具体地是公开的肉毒神经毒素,所述肉毒神经毒素以介于1.45:1与1.7:1之间的剂量比率施用到腮腺和颌下腺中。
背景技术
流口水通常表现为各种各样的临床病状,所述临床病状导致唾液溢出唇缘(称为前路流口水)或无意中溢出咽部、不自觉地进入声门和气管(称为后路流口水)的症状。由于前路流口水主要是患者在社会交往方面的问题,后路流口水还可能引起咳嗽反射完整的受试者咳嗽和刺激或无意识受试者无声地渴望咳嗽和刺激。
根据临床病状、使用国家、医学专业,术语流口水经常用于医学术语流涎、多涎或涎产生过多(ptyalism)的非专业语言。根据定义,流涎是“唾液过度溢出唇缘”,多涎是“唾液过量产生”,涎产生过多是“孕妇多涎”。这些术语和定义在其不清楚的原因以及潜在病状和问题的病理机制方面不一致地使用。
流涎的原因可以是各种各样的并且通常涉及唾液过量产生或唾液管理或消除解剖结构或生理功能的表现不佳。当然,那些因素的组合使得不可能明确区分原因,因此如上所列的症状诊断的描述语的使用相互矛盾。在某些情况下,只有唾液腺和唾液管、嘴唇、口腔和牙齿的解剖学畸形(malformations)和畸形(deformities)(唇闭合缺陷、牙齿咬合不正)导致口腔与外部世界之间的局部旁路,从而使得产生的唾液不受控制地流出。
畸形、狭窄、疤痕、瘘管和旁路可以作为口腔癌或头颈癌的永久性后果、损伤以及其外科手术并发症发生。智力残疾患者可能会永久性张嘴,从而在有或没有畸形的情况下产生相同的效果。感觉运动能力降低、口腔神经肌肉控制无效、保护反射降低、吞咽肌肉运动能力低下、吞咽频率降低或吞咽无效或吞咽困难似乎是患有选自例如以下的神经系统病状的患者先天性流涎的最常见原因:帕金森病、进行性核上性麻痹、皮质基底节变性、多系统萎缩、肌萎缩侧索硬化症(ALS)、脑瘫、中风、创伤性脑损伤(TBI)、氯氮平诱导的多涎、瑞特综合征(Rett syndrome)、安格曼综合征(Angelman syndrome)、癫痫性脑病和脑肿瘤、全咽切除术(total pharyngolaryngectomy)、环状软骨上喉切除术(supracricoidlaryngectomy)和声门上喉切除术、痴呆、或智力残疾或任何其它引起流涎或多涎的原因。如果由于吞咽的运动控制受到扰乱而不经常吞咽,则产生的未受刺激或刺激的唾液被汇集在口腔中。不受控制的张嘴和头部的顺行姿势促进汇集的唾液溢出患者的唇缘。
唾液产生也可以通过刺激性因素永久性增加,例如大量龋齿或牙垢、唾液腺肥大、胃食管反流或通过药物或毒素诱导的作为副作用的多涎(例如氯氮平、苯二氮卓类药物、抗精神病药物),从而引起唾液腺中的唾液核或神经末梢永久性活化。
可以在一定程度上以其它方式控制健康个体的唾液过量产生。在患有唾液管理障碍的患者中,控制口腔中汇集的唾液或吞咽过量产生的量的唾液的能力的上限阈值较低,因此更具挑战性。
吞咽问题的治疗选择集中在康复措施(吞咽训练、口腔运动控制训练)上,然而频繁吞咽的无意识机制很难在患有如帕金森病或ALS等进行性神经疾病的患者中进行训练和发展。因此,流涎的治疗通常集中在减少唾液产生。最早的方法使用熟知的抗胆碱能药物(例如,阿托品、异丙托溴铵、东莨菪碱、格隆溴铵、托吡卡胺),其对毒蕈碱胆碱能神经起抑制作用,所述毒蕈碱胆碱能神经控制口腔中和周围的唾液腺产生的唾液量。还测试了抗胆碱能药的几种其它衍生物,并在此适应症中使用说明书标明以外的用途。最近,美国和欧盟仅批准格隆溴铵用于治疗儿童流口水。
另一种治疗替代物是肉毒毒素,所述肉毒毒素通过肌肉内注射施用到患者以减少经过治疗的肌肉的肌肉紧张和痉挛、或多汗症。在此类患者中检测到口干是不良药物反应,并且这促使医师直接用肉毒毒素A或B治疗唾液腺,即通过将肉毒毒素A或B腺体内或实质内注射到主要唾液腺腮腺和颌下腺中。
梭菌属是厌氧菌革兰氏阳性菌属,属于厚壁菌门。梭菌属由约100种物种组成,其中包含常见的自由生活细菌以及重要的病原体,如肉毒梭菌和破伤风梭菌。两种物种分别产生神经毒素、肉毒毒素和破伤风毒素。这些神经毒素是神经细胞的钙依赖性神经递质分泌的有效抑制剂,并且是人类已知的最强毒素之一。人体内的致死剂量介于每千克体重0.1ng与1ng之间。
通过受污染的食物口服摄入肉毒毒素或在伤口中产生肉毒毒素可能引起肉毒中毒,其特征在于各种肌肉麻痹。呼吸肌麻痹可能导致受影响的个体死亡。
虽然肉毒神经毒素(BoNT)和破伤风神经毒素(TeNT)通过类似的初始生理作用机制起作用,从而抑制神经递质从受影响的神经元的轴突释放到突触中,但它们的临床反应不同。虽然肉毒神经毒素作用在周围神经系统中的肌肉神经结点和其它胆碱能突触处,从而抑制神经递质乙酰胆碱的释放并且由此引起弛缓性麻痹,但是转录到中枢神经元上的破伤风神经毒素主要作用于中枢神经系统,从而通过降解蛋白质突触小泡素来阻止抑制性神经递质GABA(γ-氨基丁酸)和甘氨酸的释放。随后脊髓运动神经元的过度活动引起激动剂和拮抗剂肌肉组织普遍收缩,这称为强直性痉挛(刚性麻痹)。
虽然破伤风神经毒素以一种免疫学上不同的类型存在,但已知肉毒神经毒素发生在七种不同的免疫原性血清型(称为BoNT/A到BoNT/H,其具有另外的亚型)中。大多数肉毒梭菌菌株产生一种神经毒素,但还描述了产生多种神经毒素的菌株。
肉毒神经毒素和破伤风神经毒素具有高度同源的氨基酸序列并且示出类似的结构域结构。它们的生物活性形式包括两条通过二硫键连接的肽链,一条约50kDa的轻链和一条约100kDa的重链。不同梭菌神经毒素之间长度不同的接头或环区位于形成二硫键的两个半胱氨酸残基之间。所述环区被未知的梭菌内切蛋白酶蛋白水解切割,以获得生物活性神经毒素。
TeNT和BoNT中毒的分子机制似乎也是类似的:进入靶神经元是通过将重链的C端部分与特异性细胞表面受体结合来介导的;然后神经毒素被受体介导的内吞作用吸收。如此形成的内体中的低pH然后引发梭菌神经毒素的构象变化,这允许其将自身嵌入内体膜中并通过内体膜转移到细胞质中,其中连接重链和轻链的二硫键被减少。然后,轻链可以选择性地切割所谓的SNARE-蛋白,所述SNARE-蛋白对于神经递质释放到突触间隙中的不同步骤是必需的,例如含神经递质的囊泡与质膜的识别、对接和融合。TeNT、BoNT/B、BoNT/D、BoNT/F和BoNT/G引起突触小泡蛋白或VAMP(囊泡相关膜蛋白)的蛋白水解裂解,BoNT/A和BoNT/E切割质膜相关蛋白SNAP-25,并且BoNT/C1切割整合质膜蛋白合成素和SNAP-25。
在肉毒梭菌中,肉毒神经毒素形成为包括神经毒性组分和无毒蛋白的蛋白质复合物。辅助蛋白质嵌入神经毒性组分,从而在不增加任何毒性作用的情况下保护其免受胃肠道中消化酶的降解。因此,大多数血清型的肉毒神经毒素具有口服毒性。例如450kDa或900kDa的复合物可从肉毒梭菌培养物中获得。
近年来,肉毒神经毒素已被用作治疗剂,例如用于治疗肌张力障碍和痉挛,并且还用于化妆品应用中,如细纹治疗。包括肉毒神经毒素复合物的制剂是市售的,例如从易普森公司(Ipsen Ltd)索斯神经科学有限公司(Solstice Neurosciences LLC)/美国世界医学有限公司(US Worldmeds LLC)或爱力根公司(Allergan Inc)获得。无任何复杂蛋白质的肉毒神经毒素的高纯度的神经毒性组分例如可从德国法兰克福梅尔茨制药有限公司(Merz Pharmaceuticals GmbH)获得。
现有技术中有一些关于在由不同潜在疾病引起的流涎患者中使用肉毒神经毒素A和B的报道。例如,Breheret等人(Annales francaises -rhino-laryngologie et dePathologie Cervico-faciale,第128卷,第5期,2011,266-271)、Barbero等人(《神经病学杂志(J Neurol.》2015年12月;262(12):2662-7)、Suskind等人(《喉内视镜(Laryngoscope)》,2002年1月;112(1):73-81)、Porta等人(《神经外科学(J NeurolNeurosurg Psychiatry)》2001年4月;70(4):538-40)、Narayanaswami等人《帕金森病相关病症(Parkinsonism Relat Disord.)》2016年9月;30:73-7)以及Castelnovo等人(《运动病症(Movement Disorders)》2013,第28卷,摘要增刊)报告了根据几种不同方案使用不同的毒素,其中不同量的毒素施用到唾液腺以治疗各种医学病状中的流涎。尽管大量研究提供了关于将肉毒神经毒素用于流涎的安全性和功效的数据,但仍有许多正在进行的讨论,所述讨论没有给出关于剂量、施用部位和所用毒素类型的明确建议。
发明目的
本发明的目的之一是提供一种用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒神经毒素,所述肉毒神经毒素长时间限制唾液腺的活性,其程度为受试者示出没有流口水,但所述肉毒神经毒素仍允许减少量的唾液产生足以用于正常的生理功能,例如作为润滑剂、作为离子储库、作为缓冲剂、作为清洁剂、用于抗微生物作用、用于凝集、用于薄膜形成、用于消化、用于品尝、用于排泄和/或水平衡。本发明的另一个目的是避免与用肉毒神经毒素治疗相关的副作用或至少减少治疗时其频率、严重性和/或持续时间。作为本发明的另外的目的,肉毒神经毒素应该在长期治疗中提供有利的治疗结果,因为潜在疾病将不受治疗的影响,因此长效疗法应该是有效且安全的,而不降低功效或损害延长的治疗的重复注射周期的安全性。
发明内容
令人惊讶的是,已经确定肉毒神经毒素可以解决这些异议中的一个或多个,如果其用于治疗与流涎或唾液产生增多相关的疾病或病状的话,其中所述肉毒神经毒素通过注射到腮腺和颌下腺中来施用,并且其中施用到腮腺中的每一个和颌下腺中的每一个的肉毒神经毒素的剂量之间的比率介于1.45:1与1.7:1之间。
具体实施方式
通过参考以下本发明的详细描述和本文所包含的实例,可以更容易地理解本发明。
在第一个实施例中,本发明涉及一种用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒神经毒素,其中所述肉毒神经毒素通过注射到腮腺和颌下腺中施用,并且其中施用到所述腮腺中的每一个和所述颌下腺中的每一个中的肉毒神经毒素的剂量之间的比率介于1.45:1与1.7:1之间。在优选的实施例中,将本发明的肉毒神经毒素施用到腮腺和颌下腺中,其中施用到腮腺中的每一个和颌下腺中的每一个的肉毒神经毒素的剂量之间的比率介于1.50:1与1.6:1之间。在特别优选的实施例中,将本发明的肉毒神经毒素施用到腮腺和颌下腺中,其中施用到腮腺中的每一个和颌下腺中的每一个的肉毒神经毒素的剂量之间的比率为1.50:1。
在另外的实施例中,本发明涉及一种治疗患者的与流涎或唾液产生增多相关的疾病或病状的方法,所述方法包括通过注射到腮腺和颌下腺中来施用治疗有效量的肉毒神经毒素,其中施用到所述腮腺中的每一个和所述颌下腺中的每一个中的肉毒神经毒素的剂量之间的比率介于1.45:1与1.7:1之间。在优选的实施例中,本发明的方法包括通过注射到腮腺和颌下腺中来施用治疗有效量的肉毒神经毒素,其中施用到所述腮腺中的每一个和所述颌下腺中的每一个的肉毒神经毒素的剂量之间的比率介于1.50:1与1.6:1之间。在特别优选的实施例中,本发明的方法包括通过注射到腮腺和颌下腺中来施用治疗有效量的肉毒神经毒素,其中施用到所述腮腺中的每一个和所述颌下腺中的每一个的肉毒神经毒素的剂量之间的比率为1.50:1。
在另外的方面,本发明总体上涉及用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒毒素。在本发明的特定实施例中,与流涎或唾液产生增多相关的疾病或病状与例如以下相关:帕金森病、进行性核上性麻痹、皮质基底节变性、多系统萎缩、肌萎缩侧索硬化症(ALS)、脑瘫、中风、创伤性脑损伤(TBI)、氯氮平诱导的多涎、瑞特综合征、安格曼综合征、癫痫性脑病、脑肿瘤、全咽切除术、环状软骨上喉切除术和声门上喉切除术、痴呆、或智力残疾(例如,全面发育迟缓、严重学习障碍)或任何其它导致流涎或多涎的原因。根据本发明的与流涎或唾液产生增多相关的疾病或病状还可以是唐氏综合征(Down′s syndrome)、史-伦-奥三氏综合征(Smith-Lemli-Opitz syndrome)、莫比乌斯综合征(syndrome)、MEGDEL综合征、贝-维综合征(Beckwith-Wiedemann syndrome)、舌头的淋巴管畸形、前岛盖综合征(Foix-Chavany-Marie syndrome)、染色体异常和遗传性疾病(如17q21缺失、家族性自主神经功能障碍、22部分三体)、艾卡尔迪综合征(Aicardi syndrome)、SMA1型、GM1神经节苷脂病或阿佩尔综合征(Apert syndrome)、肝豆状核变性、先天性脑畸形(如脑积水、小头畸形、脑桥小脑发育不全、后颅窝肿块、神经元蜡样脂褐质沉积症、巴登病、异染性脑白质营养不良、多发性关节挛缩症、脑病(encephalopathy)、平脑症或脑回肥厚)、脑损伤(如脊髓损伤、缺氧缺血性脑病、先天性弓形虫病、先天性巨细胞病毒(CMV)感染、后脑膜脑炎或后疱疹脑炎)、神经运动病症(如口腔运用障碍、蝶鞍上麻痹、鳃盖综合征、肌病、婴儿痉挛、肌强直性营养不良、杜氏肌萎缩症、I型神经纤维瘤病或线粒体病、胎儿酒精综合征或孤独症)或少年格林-巴利综合征(juvenile Guillain-BarréSyndrome)。
在本发明的特定实施例中,与流涎或唾液产生增多相关的疾病或病状与中风相关,具体地与中风后(卒中后)发生的流涎或唾液产生增多相关的疾病或病状相关。
在本发明的优选实施例中,与流涎或唾液产生增多相关的疾病或病状与例如创伤性脑损伤(TBI)、卒中后、帕金森病或非典型帕金森综合征(进行性核上性麻痹[PSP]、多系统萎缩)[MSA]、皮质基底节变性[CBD])相关。在本发明的另一个优选实施例中,与流涎或唾液产生增多相关的疾病或病状为创伤性脑损伤(TBI)、卒中后、帕金森病或非典型帕金森症(进行性核上性麻痹[PSP]、多系统萎缩)[MSA]、皮质基底节变性[CBD]),其中慢性流涎持续至少3个月,并且流涎严重度在流口水严重度分量表上为至少2分,并且频率在流口水频率分量表上为至少2分,并且在总分流口水严重度和频率量表上为至少6分。在本发明的另一个优选实施例中,与流涎或唾液产生增多相关的疾病或病状为创伤性脑损伤(TBI)、卒中后、帕金森病或非典型帕金森症(进行性核上性麻痹[PSP]、多系统萎缩)[MSA]、皮质基底节变性[CBD]),其中慢性流涎的未刺激的唾液流速为至少0.3g/min。
在另外的实施例中,本发明涉及一种药物组合物,所述药物组合物包括用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒神经毒素和药学上可接受的载剂,其中所述肉毒神经毒素通过注射到腮腺和颌下腺中施用,并且其中施用到所述腮腺中的每一个和所述颌下腺中的每一个的肉毒神经毒素的剂量之间的比率介于1.45:1与1.7:1之间。
根据本发明的一个实施例,肉毒神经毒素以介于70U与110U之间的总剂量施用到腮腺和颌下腺中。在优选的实施例中,施用到腮腺和颌下腺中的肉毒神经毒素的总剂量介于75U与100U之间。
根据本发明的一个实施例,肉毒神经毒素以75U的总剂量施用到腮腺和颌下腺中。在替代性实施例中,施用到腮腺和颌下腺中的肉毒神经毒素的总剂量为100U。
通常,根据本发明,肉毒神经毒素可以以介于0.5U/Kg体重与2.35U/Kg体重之间的总剂量施用到腮腺和颌下腺中。在特别优选的实施例中,肉毒神经毒素以介于1U/Kg体重与1.25U/Kg体重之间的总剂量施用到腮腺和颌下腺中。由于体重轻,通常如剂量表8中所呈现的向儿童施用肉毒毒素。在另一个实施例中,将高达2.5U/kg的总剂量施用到儿童的腮腺和颌下腺中。
根据本发明的另外的方面,肉毒神经毒素在肉毒神经毒素浓度介于45U/mL与55U/mL之间的范围内的水性组合物中施用。在本发明的优选实施例中,肉毒神经毒素在肉毒神经毒素浓度为50U/mL的水性组合物中施用。在特别优选的实施例中,100U小瓶的内容物将用总共2.0mL的生理盐水重构,并且施用到腮腺和颌下腺的体积为:
-腮腺:每侧0.6ml,
-颌下腺:每侧0.4ml。
如果设想了几个连续的治疗周期,如果在先前的治疗周期中发生口干或吞咽困难,则可以减少注射体积。建议根据注射者的判断进行这种减少以避免此类副作用的进一步发生。如果设想减少肉毒神经毒素施用量,则施用到腮腺和颌下腺的注射体积为:
-腮腺:每侧0.45ml,
-颌下腺:每侧0.3ml。
生物活性通常以小鼠单位(U)表示。如本文所用,1U是肉毒神经毒素的神经毒性组分的量,其在腹膜内注射后杀死50%的特定小鼠群,即小鼠i.p.LD50。用于确定肉毒神经毒素的生物活性的另一个特别有用的方法是基于细胞的测定,如例如在WO 2009/114748、WO2013/049508或WO 2014/207109中公开的。用此类基于细胞的测定获得的活性结果对应于在小鼠i.p.LD50测定中获得的活性值。针对肉毒血清型A调配物(如市售的印考肉毒毒素A(Incobotulinumtoxin A)(肉毒毒素血清型A、无复合蛋白、梅尔茨制药有限公司)或奥那肉毒毒素A(Onabotulinumtoxin A)(肉毒毒素血清型A、含有复合蛋白、爱力根公司)获得的活性结果可以使用本领域技术人员已知的转化率将其转换为其它毒素的值。例如,必需剂量的A型阿波肉毒毒素A(AbobotulinumtoxinA A)(肉毒毒素血清型A、具有复合蛋白、易普森生物制药公司(Ipsen Biopharm Limited))可以通过将印考肉毒毒素A或奥那肉毒毒素A的剂量乘以2.5到5的因子来确定。瑞马肉毒毒素B(RimabotulinumtoxinB)(肉毒毒素血清型B、索斯神经科学有限公司/美国世界医学有限公司)的剂量可以通过将印考肉毒毒素A或奥那肉毒毒素A的剂量乘以20到40的因子来计算。
在本发明的另外的实施例中,肉毒神经毒素以每个注射部位介于0.3mL与0.5mL之间的体积施用到颌下腺中并且以每个注射部位介于0.5mL到0.7mL之间的体积施用到腮腺中。在本发明的特别优选的实施例中,肉毒神经毒素以每个注射部位0.4mL的体积施用到颌下腺中并且以每个注射部位0.6mL的体积施用到腮腺中。
在本发明的另外的实施例中,将肉毒神经毒素注射到患者两侧上的每一个颌下腺的一个部位中。根据腺的解剖程度,将注射应用于腺的几何中心中。
在本发明的另一个实施例中,肉毒神经毒素被注射到患者的两侧上的每一个腮腺的一个部位中。根据腺的解剖程度,将注射应用于腺的几何中心中。
在优选的实施例中,肉毒神经毒素的总剂量注射到每一个颌下腺的一个部位中并且注射到每一个腮腺的一个部位中。
本发明的一个实施例涉及一种用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒神经毒素,其中所述肉毒神经毒素通过注射到腮腺和颌下腺中施用,并且其中施用到所述腮腺中的每一个和所述颌下腺中的每一个中的肉毒神经毒素的剂量之间的比率介于1.45:1与1.7:1之间,其中与流涎或唾液产生增多相关的疾病或病状与中风相关,并且其中将总剂量为100U的肉毒神经毒素注射到每一个颌下腺的一个部位中并注射到每一个腮腺的一个部位中。
本发明的一个实施例涉及一种用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒神经毒素,其中所述肉毒神经毒素通过注射到腮腺和颌下腺中施用,并且其中施用到所述腮腺中的每一个和所述颌下腺中的每一个中的肉毒神经毒素的剂量之间的比率为1.45:1,其中与流涎或唾液产生增加相关的疾病或病状与中风相关,其中将总剂量为100U的肉毒神经毒素分别注射到每一个颌下腺的一个部位中并且注射每一个腮腺的一个部位中,特别是注射到腺的几何中心中。
在本发明的特定实施例中,不使用超声引导将肉毒神经毒素注射到腮腺和颌下腺中。在这种情况下,腺内的目标部位通过使用如本领域技术人员所熟知的解剖学界标定向来确定。腮腺位于外耳道的下方和前方,并且位于下颌支的后方和颞骨的乳突前方。当从表面看时,腺大致呈楔形,并且当在水平剖面上看时,腺也是楔形的。腮腺很容易被触诊。为了找到腮腺可触知的标志,应该在下颌前支与胸锁乳突肌之间触诊。开始触诊每只耳朵前方,移到脸颊区域,并且然后下颌角下方。使用解剖学标志触诊腮腺表面边界,并且将肉毒神经毒素注射到腮腺中部。可以将注射剂注射到主要腺体的上半部或下半部。需要选择单个注射点。将相同的程序应用于受试者的另一侧。颌下腺位于下颌弓下方口腔底部下方,紧邻以下解剖结构。每个颌下腺位于二腹肌上方,分为由舌骨肌分开的浅叶和深叶。浅叶包括大部分腺,其中舌骨肌在其下面延伸。深叶是较小的部分。虽然颌下腺并不总是容易触诊,但其解剖位置已明确限定。注射平行于排泄管进行,尽管很少见。通过用两根手指将腺固定在下颌骨下方的位置来给颌下腺注射。针将从上向前插入口底方向,与下颌骨呈70-90度(Holsinger,2005,《唾液腺的解剖、功能和评估(Anatomy,Function,and Evaluation ofthe Salivary Glands)》)。
在其它实施例中,使用超声引导将肉毒神经毒素注射到腮腺和颌下腺中。本领域技术人员充分意识到应用超声成像技术来充分确定腺体内的目标区域的尺寸和定位。例如,可以使用>7.5MHz的高频线性换能器来识别和可视化腺。[Howlett,“腮腺的高分辨率超声评估(High resolution ultrasound assessment of the parotid gland)”(2003)《英国放射学杂志(British Journal of Radiology)》76,271-277]。
通常设想将肉毒神经毒素注射到腮腺和颌下腺中不止一次。在特定实施例中,根据本发明的肉毒神经毒素在连续的治疗周期中施用。根据本发明,治疗周期是两次施用肉毒神经毒素之间的时间间隔,即治疗周期由肉毒神经毒素的一次施用和随访期组成,直到施用下一次肉毒神经毒素注射。肉毒神经毒素优选地以至少2个、至少3个、至少4个、至少5个、至少6个、至少7个或至少8个治疗周期施用。在一个实施例中,肉毒神经毒素以2个到6个治疗周期施用,特别是以4个治疗周期施用。
肉毒神经毒素到腮腺和颌下腺中的连续两次施用之间的时间间隔可以在10周与20周之间或12周与20周之间变化。在另一个实施例中,肉毒神经毒素到腮腺和颌下腺中的连续两次施用之间的时间间隔可以在6周与10周之间变化。在优选的实施例中,肉毒神经毒素到腮腺和颌下腺中的连续两次施用之间的时间间隔可以在12周与18周之间或14周与18周之间变化。在最优选的实施例中,时间间隔为15周、16周或17周,特别是16周。
在本发明的一个实施例中,肉毒神经毒素到腮腺和颌下腺中的所有连续施用之间的时间间隔保持相同。
在本发明的一个实施例中,以至少4个连续治疗周期将肉毒神经毒素注射到腮腺和颌下腺中,其中连续施用肉毒神经毒素之间的时间间隔为16周。
通常,有几种方法可以确定用于治疗与本领域技术人员已知的流涎或唾液产生增多相关的疾病或病状的肉毒毒素的功效。用于确定用于治疗流涎或与唾液产生增多相关的疾病或病状的肉毒毒素的功效的测量和量表可以选自例如确定未刺激的唾液流速(uSFR)、平均总体变化印象量表(GICS)、流口水严重度和频率量表(DSFS)、改良帕金森病Radboud口腔运动量表(mROMP)、改良教师流口水量表(mTDS)、流口水冲击量表(DIS)、流口水指数(DQ)流口水评定量表和(DRS)和/或UPDRS流口水量表。
在特定实施例中,可以组合这些测量和量表中的至少两个以确定用于治疗流涎或与唾液产生增多相关的疾病或病状的肉毒毒素的功效。
在本发明的一个实施例中,用于治疗流涎或与唾液产生增多相关的疾病或病状的肉毒毒素用于具有基线唾液产生的患者,即未刺激的唾液流速(uSFR)介于0.1g/min到1.6g/min之间。在优选的实施例中,用于治疗流涎或与唾液产生增多相关的疾病或病状的肉毒毒素用于具有基线唾液产生的患者,即未刺激的唾液流速(uSFR)大于0.3g/min。在另一个实施例中,用于治疗流涎或与唾液产生增多相关的疾病或病状的肉毒毒素用于基线流口水严重度和频率量表(DSFS)总分≥6且严重度分项分数≥2且频率分项分数≥2的患者。通常,uSFR评分和DSFS评分的确定是本领域技术人员公知的。根据本发明,使用四个吸收性拭子收集5分钟所收集的唾液重量来确定uSFR。通过将吸收性材料(例如,四个牙科棉卷、或Salimetrics Oral)放入口腔中5分钟来进行唾液收集。吸收性材料从封闭的口腔吸附唾液,并且由于收集的唾液量而引起的吸收性材料的重量增加可以通过测量吸收性材料在放入口腔之前和之后的重量来确定。在30分钟暂停之后重复收集和测量产生的唾液量5分钟提供第二值。两个值的平均值保证了测量结果的可靠性(通过降低测量的个体内变异性)(Jongerius PH、van Limbeek J、Rotteveel JJ,“评估唾液流速:生物学变化和测量误差(Assessment of salivary flow rate:biologic variation andmeasure error)”《喉内视镜》,2004;114(10):1801-4)。
在本发明的另外的实施例中,与施用后4周内的基线相比,100U肉毒神经毒素的施用降低uSFR至少25%。在优选的实施例中,与注射后4周内的基线相比,100U肉毒神经毒素的施用降低uSFR至少30%(中值)。在本发明的另外的实施例中,与施用后8周内的基线相比,100U肉毒神经毒素的施用降低uSFR至少22%(中值)。在优选的实施例中,与注射后8周内的基线相比,100U肉毒神经毒素的施用降低uSFR至少28%(中值)。
在本发明的另一个实施例中,与施用后4周内的基线流口水相比,施用100U的肉毒神经毒素改善了患者所评估的流口水总体变化印象量表(GICS)得分,在7点李克特样量表(Likert like scale)上提高了至少+0.90分。在优选的实施例中,与注射后4周内的基线流口水相比,100U肉毒神经毒素的施用示出至少+1.00分的总体变化印象量表(GICS)改善。在本发明的另一个实施例中,与施用后8周内的基线流口水相比,施用100U的肉毒神经毒素改善了通过总体变化印象量表(GICS)测量的流口水至少+1.00分。在优选的实施例中,与注射后12周内的基线相比,施用100U的肉毒神经毒素改善了通过总体变化印象量表(GICS)测量的流口水至少+0.90分。总体变化印象量表(GICS)由李克特样量表确定,其回答了问题“与您在最后一次注射到唾液腺中之前的情况相比,作为这种治疗的结果,您对现在如何运作的总体印象是什么?”量表答案在“-3非常差”到“+3改善非常大”的范围内(Likert,Rensis(1932),“态度衡量技巧”,《心理学档案(Archives of Psychology)》,140:1–55)。
在本发明的另外的实施例中,与施用后4周内的基线相比,施用100U的肉毒神经毒素降低平均流口水严重度和频率量表(DSFS)总分至少0.90分。在优选的实施例中,与注射后4周内的基线相比,施用100U的肉毒神经毒素降低平均流口水严重度和频率量表(DSFS)总分至少1.20分。在本发明的另一个实施例中,与施用后8周内的基线相比,施用100U的肉毒神经毒素降低平均流口水严重度和频率量表(DSFS)总分至少1.50分。流口水严重度和频率量表(DSFS)由两个分量表确定,针对‘流口水频率’的4-点李克特量表和针对‘流口水严重度’的5-点李克特量表。DSFS是两个分量表的总和。评估指“过去一周”的时间段。可能的最高分为9分(Thomas-Stonell N、Greenberg J,“减少流口水的三种治疗方法和临床因素(Three treatment approaches and clinical factors in the reduction ofdrooling)”,《吞咽困难(Dysphagia)》,1988;3(2):73-8.)。
流口水严重度
流口水频率
在本发明的另外的实施例中,与施用后4周内的基线相比,施用100U的肉毒神经毒素降低平均改良帕金森病Radboud口腔运动量表(mROMP)唾液控制域总分至少3.50分。在优选的实施例中,与注射后4周内的基线相比,施用100U的肉毒神经毒素降低平均改良帕金森病Radboud口腔运动量表(mROMP)唾液控制域总分至少4.60分。在本发明的另一个实施例中,与施用后8周内的基线相比,施用100U的肉毒神经毒素降低改良帕金森病Radboud口腔运动量表(mROMP)唾液控制域总分至少5.50分。在优选的实施例中,与注射后8周内的基线相比,施用100U的肉毒神经毒素降低改良帕金森病Radboud口腔运动量表(mROMP)唾液控制域总分至少6.50分。改良帕金森病Radboud口腔运动量表(mROMP)由原始ROMP清单确定[Kalf 2011,《物理医学与机能恢复集刊(Arch.Phys.Med.Rehabil.)》]这是一份关于说话、吞咽和唾液控制领域的5-点李克特量表的荷兰23-项问卷。对ROMP进行修改(mROMP)以便实施在语言验证到美国英语期间从患者访谈产生的较少的措辞变化。mROMP现在有24个项目,所述项目具有明显可区分的响应选项和过去7天的回忆期。
在本发明的一方面,肉毒神经毒素是肉毒神经毒素复合物。例如450kDa或900kDa的复合物可从肉毒梭菌培养物中获得。根据本发明的肉毒梭菌神经毒素复合物包括神经毒性组分和无毒蛋白。辅助蛋白质嵌入神经毒性组分,从而在不增加任何毒性作用的情况下保护其免受胃肠道中消化酶的降解。
在本发明的另一方面,肉毒神经毒素是肉毒神经毒素复合物的神经毒性组分。通常,神经毒性组分的分子量为150kDa。神经毒性组分缺乏肉毒梭菌神经毒素复合物的任何其它蛋白质组分。
根据本发明的肉毒神经毒素选自包含以下的不同血清型的组:肉毒神经毒素血清型A(BoNT/A)、肉毒神经毒素血清型B(BoNT/B)、肉毒神经毒素血清型C1(BoNT/C1)、肉毒神经毒素血清型(BoNT/D)、肉毒神经毒素血清型E(BoNT/E)、肉毒神经毒素血清型F(BoNT/F)或肉毒神经毒素血清型G(BoNT/G)。肉毒神经毒素以及具体地其轻链和重链可衍生自上文指出的肉毒神经毒素的抗原性不同的血清型之一。一方面,所述肉毒神经毒素的轻链和重链是选自由以下组成的组的肉毒神经毒素的轻链和重链:BoNT/A、BoNT/B、BoNT/C1、BoNT/D、BoNT/E、BoNT/F或BoNT/G。另一方面,对本发明的所述肉毒神经毒素进行编码的多核苷酸包括如以下示出的核酸序列:SEQ ID NO:1(BoNT/A)、SEQ ID NO:3(BoNT/B)、SEQ ID NO:5(BoNT/C1)、SEQ ID NO:7(BoNT/D)、SEQ ID NO:9(BoNT/E)、SEQ ID NO:11(BoNT/F)或SEQID NO:13(BoNT/G)。此外,一方面,涵盖的是多核苷酸,所述多核苷酸包括对如以下中的任一个示出的氨基酸序列进行编码的核酸序列:SEQ ID NO:2(BoNT/A)、SEQ ID NO:4(BoNT/B)、SEQ ID NO:6(BoNT/C1)、SEQ ID NO:8(BoNT/D)、SEQ ID NO:10(BoNT/E)、SEQ ID NO:12(BoNT/F)或SEQ ID NO:14(BoNT/G)。在本发明的手段和方法的一方面,进一步涵盖的是肉毒神经毒素,所述肉毒神经毒素包括选自由以下组成的组的氨基酸序列或由所述氨基酸序列组成:SEQ ID NO:2(BoNT/A)、SEQ ID NO:4(BoNT/B)、SEQ ID NO:6(BoNT/C1)、SEQ IDNO:8(BoNT/D)、SEQ ID NO:10(BoNT/E)、SEQ ID NO:12(BoNT/F)以及SEQ ID NO:14(BoNT/G)。
另一方面,对本发明的肉毒神经毒素进行编码的所述多核苷酸是前述多核苷酸的变体,前述多核苷酸包括一个或多个核苷酸取代、缺失和/或添加,在仍另一方面,前述多核苷酸可以产生具有一个或多个氨基酸取代、缺失和/或添加的多肽。此外,另一方面,本发明的变体多核苷酸应包括:与如SEQ ID NO:1、3、5、7、9、11或13中任一个所示出的核酸序列至少40%、至少50%、至少60%、至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少96%、至少97%、至少98%或至少99%相同的核酸序列变体;或对氨基酸序列进行编码的核酸序列变体,所述氨基酸序列与SEQ ID NO:2、4、6、8、10、12或14中任一个所示出的氨基酸序列至少40%、至少50%、至少60%、至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少96%、至少97%、至少98%、或至少99%相同。如本文所用的,术语“相同”是指序列一致性,所述序列一致性的特征在于确定两个核酸序列或两个氨基酸序列之间的相同氨基酸的数目,其中可以对序列进行比对,从而获得最高级顺序匹配。可以使用在计算机程序中编码的公开技术或方法计算,如例如BLASTP、BLASTN或FASTA(Altschul,1990,《分子生物杂志(J Mol Biol)》215,403)。一方面,百分比一致性是在整个氨基酸序列上计算的。基于各种算法的一系列程序可供技术人员使用以对不同的序列进行比较。在这种情况下,Needleman和Wunsch或Smith和Waterman的算法给出了特别可靠的结果。为了进行序列比对,可以使用程序PileUp(Higgins,1989,CABIOS 5,151)或程序Gap和BestFit(Needleman,1970,《分子生物杂志》48;443;Smith,1981,《高级应用数学2(Adv Appl Math2)》,482,所述程序为GCG软件包(遗传学计算机集团(Genetics Computer Group)1991,575,《科学驱动(Science Drive)》,麦迪逊,威斯康星州,美国,53711)。在本发明的另一方面,用以下设置在整个序列区域中使用程序GAP来确定以百分比(%)为单位的上述序列一致性值:间隙重量:50,长度重量:3,平均匹配:10.000和平均不匹配:0.000,除非另有说明,否则其应始终用作序列比对的标准设置。一方面,上述变体多核苷酸中的每一个对多肽进行编码,所述多肽保留相应的内毒神经毒素的生物学特性中的一个或多个,并且另一方面,所述多肽保留相应的内毒神经毒素的所有生物学特性,即BoNT/A、BoNT/B、BoNT/C1、BoNT/D,BoNT/E、BoNT/F或BoNT/G。本领域技术人员将理解,仅在蛋白水解活化后才维持完整的生物活性,即使可以想到未处理的前体可以发挥一些生物学功能或具有部分活性。如本文所用的“生物学特性”是指(a)受体结合、(b)内化、(c)跨内体膜转运到胞质溶胶中、和/或(d)参与突触囊泡膜融合的蛋白质的内蛋白水解酶裂解。用于评估生物活性的体内测定包含小鼠LD50测定和离体小鼠膈肌测定,如Pearce等人(Pearce,1994,《有毒物质药理学应用(Toxicol.Appl.Pharmacol.)》128:69-77)和Dressler等人(Dressler,2005,《运动障碍(Mov.Disord.)》20:1617-1619、Keller 2006,《神经系统科学(Neuroscience)》139:629-637)所述的或如WO 2009/114748、WO 2014/207109或WO 2013/049508中所述的。生物活性通常以小鼠单位(U)表示。如本文所用,1U是肉毒神经毒素的神经毒性组分的量,其在腹膜内注射后杀死50%的特定小鼠群,即小鼠i.p.LD50。另一方面,变体多核苷酸可以对肉毒神经毒素进行编码,所述肉毒神经毒素具有改善或改变的生物学特性,例如,所述肉毒神经毒素可以包括切割位点,所述切割位点针对酶识别而改善或者可以针对受体结合或上文指定的任何其它特性而改善。用于确定肉毒神经毒素的生物活性的特别有用的方法是基于细胞的测定,如例如WO 2009/114748、WO 2013/049508或WO 2014/207109中所公开的。
不受理论束缚,此外设想,特别是不含复合蛋白(印考肉毒毒素A)的肉毒神经毒素的调配物,即相比于具有复合蛋白质的其它肉毒神经毒素(奥那肉毒毒素A,阿波肉毒毒素A,瑞马肉毒毒素B,或具有复合蛋白的其它毒素),缺乏肉毒梭菌神经毒素复合物的任何其它蛋白质组分的肉毒神经毒素的神经毒性组分允许胆碱能神经传递的临床可逆的功能性失活而不破坏唾液腺和唾液管的细胞内结构。使用缺乏肉毒梭菌神经毒素复合物的任何其它蛋白质组分的肉毒神经毒素的神经毒性组分也不会引起腺泡细胞的任何物理损伤,如在肉毒毒素注射后儿童的切除的颌下腺唾液腺中所述[Mosseri,2016,耳鼻喉科-头颈外科]。
一般来说,肉毒神经毒素阻断神经末梢是不可逆的;然而,临床效果是暂时的,因为新的神经末梢会萌芽,从而产生新的连接。复合蛋白被认为是用于治疗的生物学上无活性的化合物,并且它们通常被认为对肌肉内注射中使用的用于治疗痉挛、肌张力障碍、多汗症、头痛、抑郁、尿逼尿肌痉挛或美学适应症(如眉间皱眉纹或皱纹)的肉毒神经毒素的功效不起任何作用。
复合蛋白质是梭菌蛋白质的残余物,其来源于细菌肉毒梭菌。这些蛋白质与肉毒神经毒素蛋白复合物的神经毒性组分一起产生,并且它们在侵袭性环境(例如,胃中的酸性条件)中起到保护毒素的基本作用,并且它们通过肠子上皮屏障帮助毒素内化。复合蛋白由血凝素和非血凝素组成,并且被认为是肉毒毒素蛋白复合物的无毒蛋白。血凝素(HA)被描述为通过直接结合E-钙粘蛋白来破坏肠中的细胞间上皮屏障[Fujinaga,2009,《毒素(Toxicon)》[][Sugawara等人,2010《细胞生物学(J.Cell Biol)》,[],[Lee,2014,《科学(Science)》[]。在唾液腺分泌上皮中,插入的导管上皮和条纹导管上皮从类似于肠上皮的外胚层的胚线发展而成。在唾液腺的紧密连接中特别关注的是钙粘蛋白家族的成员,其在唾液腺发育、组织组织化和细胞分化中起作用。上皮(E)-钙粘蛋白是上皮组织中的主要细胞-细胞粘附分子,并且被认为是上皮表型的主要组织者。[Davies,2006,《发育细胞(Development Cell)》]。在早期形态发生中,E-钙粘蛋白和β-连环蛋白可能参与唾液腺重塑,而在细胞分化过程中,它们形成稳定的细胞-细胞接触,并可以与Rho GTPases在唾液细胞极性的建立和维持中协作“[Baker,2010,《生物医学与生物技术杂志(Journal ofBiomedicine and Biotechnology)》。独特的细胞间结构(如E-钙粘蛋白)在肠道和唾液腺上皮细胞极化中起着基础作用。因此,E-钙粘蛋白与肉毒毒素的复合蛋白的干扰会干扰唾液腺的正常生物活性。例如,Xu和Shan证明,在BoNT/A(中国甘肃兰州生化公司(Biochemical Co.))(即含有复合蛋白的肉毒神经毒素)施用到大鼠颌下腺后,腺泡细胞膜上的水通道蛋白(AQP5)被下调,其可能是去神经的第二次效果(Xu等人,2015《牙科研究杂志(Journal of Dental Research)》;Shan等人,2013《国际口腔科学杂志(International Journal of Oral Science)》)。
为了制备包括肉毒神经毒素的药物制剂,神经毒素可以通过依赖于所期望的应用目的的本领域已知的各种技术来调配。例如,(生物活性的)肉毒神经毒素可以与一种或多种药学上可接受的载剂组合用作药物组合物。一种或多种药学上可接受的载剂必须是“可接受的”,意思是与调配物的其它成分相容并且对其接受者无害。所用的药物载剂可以包含固体、凝胶或液体。固体载剂的实例为乳糖、石膏粉、蔗糖、滑石粉、明胶、琼脂、果胶、阿拉伯胶、硬脂酸镁、硬脂酸等。液体载剂的实例为甘油、磷酸盐缓冲盐水溶液、水、乳液、各种类型的润湿剂等。合适的载剂包括上文提到的那些载剂和本领域熟知的其它载剂,参见例如《雷明顿药物科学(Remington's Pharmaceutical Sciences)》,宾夕法尼亚州伊斯顿麦克出版公司(Mack Publishing Company)。一方面,药物组合物可以在施用之前溶解在稀释剂中。还选择稀释剂以便不影响肉毒神经毒素产品的生物活性。此类稀释剂的实例为蒸馏水或生理盐水。此外,药物组合物或调配物还可以包含其它载剂或无毒、非治疗性、非免疫原性稳定剂等。因此,一方面,调配的肉毒神经毒素产品可以以液体或冻干形式存在。一方面,其可以与甘油、蛋白质稳定剂(HSA)或非蛋白质稳定剂如聚乙烯吡咯烷酮(PVP)、透明质酸或游离氨基酸一起存在。一方面,合适的非蛋白质稳定剂公开于WO 2005/007185或WO 2006/020208中。包括根据本发明的肉毒神经毒素的针对HSA稳定的调配物的合适的调配物在例如US 8,398,998 B2中公开。调配的肉毒神经毒素产品可以以治疗有效量或用于美容目的用于治疗人或动物的各种疾病或病症。
实例
一般程序:进行临床试验,其中连续注射4次,随后各自观察16周,即连续4个治疗周期。在每个治疗周期结束时,检查受试者是否有资格进入下一个周期。与安慰剂相比,第一个治疗周期(主要期[MP])在NT 201的两个不同剂量水平(即不含复合蛋白的肉毒毒素血清型A,印考肉毒毒素A)(75U和100U)下进行。受试者以2:2:1(75U:100U:安慰剂)的比率随机分配到相应的治疗。将印考肉毒毒素A在生理盐水中以50U/mL的浓度重构,并且在100U剂量组中,患者分别在每个腮腺中接受30U毒素,并且在每个颌下腺中接受20U,并且在75U剂量组中,患者分别在每个腮腺中接受22.5U毒素并且在每个颌下腺中接受15U。在两个剂量组中,分配给每个腮腺和颌下腺的总剂量被注射到相应的腺的一个部位中。MP之后是剂量盲法延长期的3个连续治疗周期,其中受试者以与在MP中相同的方式接受75U或100U NT201。在MP期间,接受安慰剂的受试者在延长期期间以1:1随机化以接受75U或100U NT 201,因此总剂量随机化比率为1:1。试验MP的结果示出75U和100U剂量两者都达到临床有关性的治疗效果。它们被总结如下。
实例1:安慰剂对照主要期(uSFR)的结果
总体而言,在研究的MP期间治疗了184名患有慢性麻烦性流涎的受试者。所述研究有两个共同的主要疗效终点。共同主要疗效终点之一是未刺激的唾液流速(uSFR)从基线到第4周的变化(参见表1随时间的平均变化)。在所有时间点,在两个NT 201治疗组中uSFR有效地降低,其效果在NT 201 100U剂量组中更明显,如图1所示。在第4周,NT 201 100U组示出优于安慰剂的统计学上显著的优势(p=0.004)。在第8周和第12周达到p-值小于0.05(表1)的NT 201 75U中的平均uSFR值(p-值分别为0.022和0.019)。在NT 201 100U和NT 20175U两组中观察到的治疗效果可以被认为是临床相关的。
表1:在基线处的平均uSFR[g/min]和从基线随时间推移(FAS)的平均uSFR变化
实例2:安慰剂对照主要期(GICS)的结果
另一个共同主要疗效终点是在第4周通过总体变化印象量表(GICS)测量的受试者的总体功能量表的改善。GICS是7-点李克特量表,由受试者回答问题“与您在最后一次注射到唾液腺中之前的情况相比,作为这种治疗的结果,您对现在如何运作的总体印象是什么?”两个剂量组都有所改善。在第4周看到了100U治疗组优于安慰剂组的统计学上显著的差异(p=0.002,表2,图2)。在第4周,与安慰剂相比,75U组显示出数值上更好的结果,但差异很快错过了统计学显著性(p=0.055)。然而,在第8周和第12周,两个剂量组中达到了小于0.05的p-值,并在第16周在100U的剂量组中达到如在图2所呈现的。
表2:随时间推移的平均受试者的GICS值(FAS)
实例3:安慰剂对照主要期(GICS)的结果
临床上认为有意义的流口水改善的针对GICS终点的预定义响应标准为量表上至少一个点的改善(最低限度地改善)。所有治疗组的响应者分析结果列于表3和图3中。
表3:受试者的GICS中的反应率(FAS)
在整个主要时期,安慰剂组的反应率低于两个NT 201治疗组的反应率。它从28.6%(第8周)变化到第2周的48.6%。在两个NT 201组中,在第8周达到最大受试者的GICS反应率,NT 201 75U组为68.1%,NT 201 100U组为76.4%。诸位发明人认为这些比率是NT201 75U和100U剂量组的临床有意义性的证据。
实例4:安慰剂对照主要期的结果(DSFS)
还评估了主观终点流口水严重度和频率量表(DSFS)。DSFS由两个分量表组成:针对“流口水频率”的4-点李克特量表和针对“流口水严重度”的5-点李克特量表。DSFS的描述性分析示出,与安慰剂组无相关改善相比,两个NT 201治疗组中有流涎的临床相关改善。从基线随时间推移的平均总和分变化在100U治疗组中在第8周最高,改善了-1.89,随后在75U治疗组中在第12周改善了-1.76,如表4和图4所呈现的。通过混合模型重复测量(MMRM)的治疗比较揭示,与第4周、第8周和第12周的安慰剂相比,两个NT 201组的p-值都<0.05。
表4:在基线处的平均DSFS总分和从基线随时间推移的平均DSFS总分变化(FAS)
实例5:安慰剂对照主要期(mROMP)的结果
最后,使用流口水分量表(包含5-点李克特量表的9-项问卷)评估改良帕金森病Radboud口腔运动量表(mROMP)。与表5和图5中所呈现的安慰剂组相比,两个NT 201个治疗组在mROMP流口水方面都示出更好的功效结果。从基线随时间推移的平均变化在100U治疗组中在第8周达到最大改善-6.58并且在75U治疗组中在第12周达到最大改善-6.77。诸位发明人得出结论,在两个剂量组中观察到的治疗效果优于安慰剂的效果,并且NT 201效果在所有测量中是一致的并且在整个观察期间是稳健的以证实两种剂量的适当临床相关性。
表5:从研究基线到第4周MP、第8周MP、第12周MP和第16周MP的mROMP流口水分数变化(FAS,OC)
实例6:对安慰剂对照主要期(mROMP)的结果的子组分析
通过病因学的子组分析示出,在NT 201 100U组中,中风后患有流涎的受试者的uSFR平均下降比患有与帕金森病或非典型帕金森症相关的流涎的受试者更高(表6)。
表6:对从研究基线到第4周-MP的uSFR变化的子组分析(完整分析集FAS,观察到的病例OC)
实例7:16周间隔的3个连续治疗周期的功效
16周间隔的3个连续治疗周期的功效结果为流涎的进一步改善提供了证据。还评估了从研究基线到第二次注射后所有观察时间点的uSFR变化以及从每次注射(第一次注射后第16周、32周和48周)到相应的评估时间点(第一次注射后第20周、36周和52周)的变化以及从每次注射到周期结束/研究随访结束(第一次注射后第32、48和64周)的变化。
表7中展示了在没有安慰剂对照组的延长期(EP)的周期基线时的uSFR的汇总统计数据。(随机分配到处于MP的安慰剂组的受试者在相同的设置中以EP的1:1随机化比率随机分配到75U或100U剂量组,MP中的75U或100U剂量组中的受试者在EP中维持其剂量)。两个NT201治疗组中EP的平均uSFR在第2周期基线时最高并且在第4周期基线时最低。另外,NT 20175U组中每个周期基线的平均uSFR略高于NT 201 100U组。当在延长期内分析GICS、DSFS和mROMP的NT201 100U和NT201 75U时,观察到类似的流涎改善。
表7:所有周期基线-EP的平均uSFR(安全评估集SES-EP、观察到的案例OC)
表8:施用到儿童腮腺和颌下腺中的肉毒毒素的剂量表.
序列表
<110> 梅尔兹制药公司
<120> 肉毒神经毒素在治疗流涎中的改进的用途
<130> 2516-000-PCT
<150> EP17162719.3
<151> 2017-03-24
<160> 14
<170> BiSSAP 1.3.5
<210> 1
<211> 3891
<212> DNA
<213> 肉毒梭菌(Clostridium botulinum)
<400> 1
atgccatttg ttaataaaca atttaattat aaagatcctg taaatggtgt tgatattgct 60
tatataaaaa ttccaaatgc aggacaaatg caaccagtaa aagcttttaa aattcataat 120
aaaatatggg ttattccaga aagagataca tttacaaatc ctgaagaagg agatttaaat 180
ccaccaccag aagcaaaaca agttccagtt tcatattatg attcaacata tttaagtaca 240
gataatgaaa aagataatta tttaaaggga gttacaaaat tatttgagag aatttattca 300
actgatcttg gaagaatgtt gttaacatca atagtaaggg gaataccatt ttggggtgga 360
agtacaatag atacagaatt aaaagttatt gatactaatt gtattaatgt gatacaacca 420
gatggtagtt atagatcaga agaacttaat ctagtaataa taggaccctc agctgatatt 480
atacagtttg aatgtaaaag ctttggacat gaagttttga atcttacgcg aaatggttat 540
ggctctactc aatacattag atttagccca gattttacat ttggttttga ggagtcactt 600
gaagttgata caaatcctct tttaggtgca ggcaaatttg ctacagatcc agcagtaaca 660
ttagcacatg aacttataca tgctggacat agattatatg gaatagcaat taatccaaat 720
agggttttta aagtaaatac taatgcctat tatgaaatga gtgggttaga agtaagcttt 780
gaggaactta gaacatttgg gggacatgat gcaaagttta tagatagttt acaggaaaac 840
gaatttcgtc tatattatta taataagttt aaagatatag caagtacact taataaagct 900
aaatcaatag taggtactac tgcttcatta cagtatatga aaaatgtttt taaagagaaa 960
tatctcctat ctgaagatac atctggaaaa ttttcggtag ataaattaaa atttgataag 1020
ttatacaaaa tgttaacaga gatttacaca gaggataatt ttgttaagtt ttttaaagta 1080
cttaacagaa aaacatattt gaattttgat aaagccgtat ttaagataaa tatagtacct 1140
aaggtaaatt acacaatata tgatggattt aatttaagaa atacaaattt agcagcaaac 1200
tttaatggtc aaaatacaga aattaataat atgaatttta ctaaactaaa aaattttact 1260
ggattgtttg aattttataa gttgctatgt gtaagaggga taataacttc taaaactaaa 1320
tcattagata aaggatacaa taaggcatta aatgatttat gtatcaaagt taataattgg 1380
gacttgtttt ttagtccttc agaagataat tttactaatg atctaaataa aggagaagaa 1440
attacatctg atactaatat agaagcagca gaagaaaata ttagtttaga tttaatacaa 1500
caatattatt taacctttaa ttttgataat gaacctgaaa atatttcaat agaaaatctt 1560
tcaagtgaca ttataggcca attagaactt atgcctaata tagaaagatt tcctaatgga 1620
aaaaagtatg agttagataa atatactatg ttccattatc ttcgtgctca agaatttgaa 1680
catggtaaat ctaggattgc tttaacaaat tctgttaacg aagcattatt aaatcctagt 1740
cgtgtttata catttttttc ttcagactat gtaaagaaag ttaataaagc tacggaggca 1800
gctatgtttt taggctgggt agaacaatta gtatatgatt ttaccgatga aactagcgaa 1860
gtaagtacta cggataaaat tgcggatata actataatta ttccatatat aggacctgct 1920
ttaaatatag gtaatatgtt atataaagat gattttgtag gtgctttaat attttcagga 1980
gctgttattc tgttagaatt tataccagag attgcaatac ctgtattagg tacttttgca 2040
cttgtatcat atattgcgaa taaggttcta accgttcaaa caatagataa tgctttaagt 2100
aaaagaaatg aaaaatggga tgaggtctat aaatatatag taacaaattg gttagcaaag 2160
gttaatacac agattgatct aataagaaaa aaaatgaaag aagctttaga aaatcaagca 2220
gaagcaacaa aggctataat aaactatcag tataatcaat atactgagga agagaaaaat 2280
aatattaatt ttaatattga tgatttaagt tcgaaactta atgagtctat aaataaagct 2340
atgattaata taaataaatt tttgaatcaa tgctctgttt catatttaat gaattctatg 2400
atcccttatg gtgttaaacg gttagaagat tttgatgcta gtcttaaaga tgcattatta 2460
aagtatatat atgataatag aggaacttta attggtcaag tagatagatt aaaagataaa 2520
gttaataata cacttagtac agatatacct tttcagcttt ccaaatacgt agataatcaa 2580
agattattat ctacatttac tgaatatatt aagaatatta ttaatacttc tatattgaat 2640
ttaagatatg aaagtaatca tttaatagac ttatctaggt atgcatcaaa aataaatatt 2700
ggtagtaaag taaattttga tccaatagat aaaaatcaaa ttcaattatt taatttagaa 2760
agtagtaaaa ttgaggtaat tttaaaaaat gctattgtat ataatagtat gtatgaaaat 2820
tttagtacta gcttttggat aagaattcct aagtatttta acagtataag tctaaataat 2880
gaatatacaa taataaattg tatggaaaat aattcaggat ggaaagtatc acttaattat 2940
ggtgaaataa tctggacttt acaggatact caggaaataa aacaaagagt agtttttaaa 3000
tacagtcaaa tgattaatat atcagattat ataaacagat ggatttttgt aactatcact 3060
aataatagat taaataactc taaaatttat ataaatggaa gattaataga tcaaaaacca 3120
atttcaaatt taggtaatat tcatgctagt aataatataa tgtttaaatt agatggttgt 3180
agagatacac atagatatat ttggataaaa tattttaatc tttttgataa ggaattaaat 3240
gaaaaagaaa tcaaagattt atatgataat caatcaaatt caggtatttt aaaagacttt 3300
tggggtgatt atttacaata tgataaacca tactatatgt taaatttata tgatccaaat 3360
aaatatgtcg atgtaaataa tgtaggtatt agaggttata tgtatcttaa agggcctaga 3420
ggtagcgtaa tgactacaaa catttattta aattcaagtt tgtatagggg gacaaaattt 3480
attataaaaa aatatgcttc tggaaataaa gataatattg ttagaaataa tgatcgtgta 3540
tatattaatg tagtagttaa aaataaagaa tataggttag ctactaatgc atcacaggca 3600
ggcgtagaaa aaatactaag tgcattagaa atacctgatg taggaaatct aagtcaagta 3660
gtagtaatga agtcaaaaaa tgatcaagga ataacaaata aatgcaaaat gaatttacaa 3720
gataataatg ggaatgatat aggctttata ggatttcatc agtttaataa tatagctaaa 3780
ctagtagcaa gtaattggta taatagacaa atagaaagat ctagtaggac tttgggttgc 3840
tcatgggaat ttattcctgt agatgatgga tggggagaaa ggccactgta a 3891
<210> 2
<211> 1296
<212> PRT
<213> 肉毒梭菌(Clostridium botulinum)
<400> 2
Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
1 5 10 15
Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
20 25 30
Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg
35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu
50 55 60
Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr
65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu
85 90 95
Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val
100 105 110
Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
115 120 125
Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
130 135 140
Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
145 150 155 160
Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
210 215 220
Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
260 265 270
Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
275 280 285
Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
290 295 300
Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
355 360 365
Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
370 375 380
Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
385 390 395 400
Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
420 425 430
Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
435 440 445
Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe
450 455 460
Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu
465 470 475 480
Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu
485 490 495
Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro
500 505 510
Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu
515 520 525
Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu
530 535 540
Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu
545 550 555 560
His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu
565 570 575
Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys
580 585 590
Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu
595 600 605
Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr
610 615 620
Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu
645 650 655
Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala
660 665 670
Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys
675 680 685
Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu
690 695 700
Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys
705 710 715 720
Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu
725 730 735
Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn
740 745 750
Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp
755 760 765
Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile
770 775 780
Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met
785 790 795 800
Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys
805 810 815
Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly
820 825 830
Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp
835 840 845
Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser
850 855 860
Thr Phe Thr Glu Tyr Ile Lys Asn Ile Ile Asn Thr Ser Ile Leu Asn
865 870 875 880
Leu Arg Tyr Glu Ser Asn His Leu Ile Asp Leu Ser Arg Tyr Ala Ser
885 890 895
Lys Ile Asn Ile Gly Ser Lys Val Asn Phe Asp Pro Ile Asp Lys Asn
900 905 910
Gln Ile Gln Leu Phe Asn Leu Glu Ser Ser Lys Ile Glu Val Ile Leu
915 920 925
Lys Asn Ala Ile Val Tyr Asn Ser Met Tyr Glu Asn Phe Ser Thr Ser
930 935 940
Phe Trp Ile Arg Ile Pro Lys Tyr Phe Asn Ser Ile Ser Leu Asn Asn
945 950 955 960
Glu Tyr Thr Ile Ile Asn Cys Met Glu Asn Asn Ser Gly Trp Lys Val
965 970 975
Ser Leu Asn Tyr Gly Glu Ile Ile Trp Thr Leu Gln Asp Thr Gln Glu
980 985 990
Ile Lys Gln Arg Val Val Phe Lys Tyr Ser Gln Met Ile Asn Ile Ser
995 1000 1005
Asp Tyr Ile Asn Arg Trp Ile Phe Val Thr Ile Thr Asn Asn Arg Leu
1010 1015 1020
Asn Asn Ser Lys Ile Tyr Ile Asn Gly Arg Leu Ile Asp Gln Lys Pro
1025 1030 1035 1040
Ile Ser Asn Leu Gly Asn Ile His Ala Ser Asn Asn Ile Met Phe Lys
1045 1050 1055
Leu Asp Gly Cys Arg Asp Thr His Arg Tyr Ile Trp Ile Lys Tyr Phe
1060 1065 1070
Asn Leu Phe Asp Lys Glu Leu Asn Glu Lys Glu Ile Lys Asp Leu Tyr
1075 1080 1085
Asp Asn Gln Ser Asn Ser Gly Ile Leu Lys Asp Phe Trp Gly Asp Tyr
1090 1095 1100
Leu Gln Tyr Asp Lys Pro Tyr Tyr Met Leu Asn Leu Tyr Asp Pro Asn
1105 1110 1115 1120
Lys Tyr Val Asp Val Asn Asn Val Gly Ile Arg Gly Tyr Met Tyr Leu
1125 1130 1135
Lys Gly Pro Arg Gly Ser Val Met Thr Thr Asn Ile Tyr Leu Asn Ser
1140 1145 1150
Ser Leu Tyr Arg Gly Thr Lys Phe Ile Ile Lys Lys Tyr Ala Ser Gly
1155 1160 1165
Asn Lys Asp Asn Ile Val Arg Asn Asn Asp Arg Val Tyr Ile Asn Val
1170 1175 1180
Val Val Lys Asn Lys Glu Tyr Arg Leu Ala Thr Asn Ala Ser Gln Ala
1185 1190 1195 1200
Gly Val Glu Lys Ile Leu Ser Ala Leu Glu Ile Pro Asp Val Gly Asn
1205 1210 1215
Leu Ser Gln Val Val Val Met Lys Ser Lys Asn Asp Gln Gly Ile Thr
1220 1225 1230
Asn Lys Cys Lys Met Asn Leu Gln Asp Asn Asn Gly Asn Asp Ile Gly
1235 1240 1245
Phe Ile Gly Phe His Gln Phe Asn Asn Ile Ala Lys Leu Val Ala Ser
1250 1255 1260
Asn Trp Tyr Asn Arg Gln Ile Glu Arg Ser Ser Arg Thr Leu Gly Cys
1265 1270 1275 1280
Ser Trp Glu Phe Ile Pro Val Asp Asp Gly Trp Gly Glu Arg Pro Leu
1285 1290 1295
<210> 3
<211> 3876
<212> DNA
<213> 肉毒梭菌(Clostridium botulinum)
<400> 3
atgccagtta caataaataa ttttaattat aatgatccta ttgataataa taatattatt 60
atgatggagc ctccatttgc gagaggtacg gggagatatt ataaagcttt taaaatcaca 120
gatcgtattt ggataatacc ggaaagatat acttttggat ataaacctga ggattttaat 180
aaaagttccg gtatttttaa tagagatgtt tgtgaatatt atgatccaga ttacttaaat 240
actaatgata aaaagaatat atttttacaa acaatgatca agttatttaa tagaatcaaa 300
tcaaaaccat tgggtgaaaa gttattagag atgattataa atggtatacc ttatcttgga 360
gatagacgtg ttccactcga agagtttaac acaaacattg ctagtgtaac tgttaataaa 420
ttaatcagta atccaggaga agtggagcga aaaaaaggta ttttcgcaaa tttaataata 480
tttggacctg ggccagtttt aaatgaaaat gagactatag atataggtat acaaaatcat 540
tttgcatcaa gggaaggctt cgggggtata atgcaaatga agttttgccc agaatatgta 600
agcgtattta ataatgttca agaaaacaaa ggcgcaagta tatttaatag acgtggatat 660
ttttcagatc cagccttgat attaatgcat gaacttatac atgttttaca tggattatat 720
ggcattaaag tagatgattt accaattgta ccaaatgaaa aaaaattttt tatgcaatct 780
acagatgcta tacaggcaga agaactatat acatttggag gacaagatcc cagcatcata 840
actccttcta cggataaaag tatctatgat aaagttttgc aaaattttag agggatagtt 900
gatagactta acaaggtttt agtttgcata tcagatccta acattaatat taatatatat 960
aaaaataaat ttaaagataa atataaattc gttgaagatt ctgagggaaa atatagtata 1020
gatgtagaaa gttttgataa attatataaa agcttaatgt ttggttttac agaaactaat 1080
atagcagaaa attataaaat aaaaactaga gcttcttatt ttagtgattc cttaccacca 1140
gtaaaaataa aaaatttatt agataatgaa atctatacta tagaggaagg gtttaatata 1200
tctgataaag atatggaaaa agaatataga ggtcagaata aagctataaa taaacaagct 1260
tatgaagaaa ttagcaagga gcatttggct gtatataaga tacaaatgtg taaaagtgtt 1320
aaagctccag gaatatgtat tgatgttgat aatgaagatt tgttctttat agctgataaa 1380
aatagttttt cagatgattt atctaaaaac gaaagaatag aatataatac acagagtaat 1440
tatatagaaa atgacttccc tataaatgaa ttaattttag atactgattt aataagtaaa 1500
atagaattac caagtgaaaa tacagaatca cttactgatt ttaatgtaga tgttccagta 1560
tatgaaaaac aacccgctat aaaaaaaatt tttacagatg aaaataccat ctttcaatat 1620
ttatactctc agacatttcc tctagatata agagatataa gtttaacatc ttcatttgat 1680
gatgcattat tattttctaa caaagtttat tcattttttt ctatggatta tattaaaact 1740
gctaataaag tggtagaagc aggattattt gcaggttggg tgaaacagat agtaaatgat 1800
tttgtaatcg aagctaataa aagcaatact atggataaaa ttgcagatat atctctaatt 1860
gttccttata taggattagc tttaaatgta ggaaatgaaa cagctaaagg aaattttgaa 1920
aatgcttttg agattgcagg agccagtatt ctactagaat ttataccaga acttttaata 1980
cctgtagttg gagccttttt attagaatca tatattgaca ataaaaataa aattattaaa 2040
acaatagata atgctttaac taaaagaaat gaaaaatgga gtgatatgta cggattaata 2100
gtagcgcaat ggctctcaac agttaatact caattttata caataaaaga gggaatgtat 2160
aaggctttaa attatcaagc acaagcattg gaagaaataa taaaatacag atataatata 2220
tattctgaaa aagaaaagtc aaatattaac atcgatttta atgatataaa ttctaaactt 2280
aatgagggta ttaaccaagc tatagataat ataaataatt ttataaatgg atgttctgta 2340
tcatatttaa tgaaaaaaat gattccatta gctgtagaaa aattactaga ctttgataat 2400
actctcaaaa aaaatttgtt aaattatata gatgaaaata aattatattt gattggaagt 2460
gcagaatatg aaaaatcaaa agtaaataaa tacttgaaaa ccattatgcc gtttgatctt 2520
tcaatatata ccaatgatac aatactaata gaaatgttta ataaatataa tagcgaaatt 2580
ttaaataata ttatcttaaa tttaagatat aaggataata atttaataga tttatcagga 2640
tatggggcaa aggtagaggt atatgatgga gtcgagctta atgataaaaa tcaatttaaa 2700
ttaactagtt cagcaaatag taagattaga gtgactcaaa atcagaatat catatttaat 2760
agtgtgttcc ttgattttag cgttagcttt tggataagaa tacctaaata taagaatgat 2820
ggtatacaaa attatattca taatgaatat acaataatta attgtatgaa aaataattcg 2880
ggctggaaaa tatctattag gggtaatagg ataatatgga ctttaattga tataaatgga 2940
aaaaccaaat cggtattttt tgaatataac ataagagaag atatatcaga gtatataaat 3000
agatggtttt ttgtaactat tactaataat ttgaataacg ctaaaattta tattaatggt 3060
aagctagaat caaatacaga tattaaagat ataagagaag ttattgctaa tggtgaaata 3120
atatttaaat tagatggtga tatagataga acacaattta tttggatgaa atatttcagt 3180
atttttaata cggaattaag tcaatcaaat attgaagaaa gatataaaat tcaatcatat 3240
agcgaatatt taaaagattt ttggggaaat cctttaatgt acaataaaga atattatatg 3300
tttaatgcgg ggaataaaaa ttcatatatt aaactaaaga aagattcacc tgtaggtgaa 3360
attttaacac gtagcaaata taatcaaaat tctaaatata taaattatag agatttatat 3420
attggagaaa aatttattat aagaagaaag tcaaattctc aatctataaa tgatgatata 3480
gttagaaaag aagattatat atatctagat ttttttaatt taaatcaaga gtggagagta 3540
tatacctata aatattttaa gaaagaggaa gaaaaattgt ttttagctcc tataagtgat 3600
tctgatgagt tttacaatac tatacaaata aaagaatatg atgaacagcc aacatatagt 3660
tgtcagttgc tttttaaaaa agatgaagaa agtactgatg agataggatt gattggtatt 3720
catcgtttct acgaatctgg aattgtattt gaagagtata aagattattt ttgtataagt 3780
aaatggtact taaaagaggt aaaaaggaaa ccatataatt taaaattggg atgtaattgg 3840
cagtttattc ctaaagatga agggtggact gaataa 3876
<210> 4
<211> 1291
<212> PRT
<213> 肉毒梭菌(Clostridium botulinum)
<400> 4
Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn
1 5 10 15
Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg
20 25 30
Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu
35 40 45
Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly
50 55 60
Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn
65 70 75 80
Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe
85 90 95
Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile
100 105 110
Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu
115 120 125
Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn
130 135 140
Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile
145 150 155 160
Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly
165 170 175
Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln
180 185 190
Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu
195 200 205
Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro
210 215 220
Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr
225 230 235 240
Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe
245 250 255
Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile
275 280 285
Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn
290 295 300
Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr
305 310 315 320
Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly
325 330 335
Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu
340 345 350
Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys
355 360 365
Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys
370 375 380
Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile
385 390 395 400
Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile
405 410 415
Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr
420 425 430
Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp
435 440 445
Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser
450 455 460
Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn
465 470 475 480
Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp
485 490 495
Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr
500 505 510
Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys
515 520 525
Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln
530 535 540
Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp
545 550 555 560
Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp
565 570 575
Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly
580 585 590
Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser
595 600 605
Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile
610 615 620
Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu
625 630 635 640
Asn Ala Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro
645 650 655
Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile
660 665 670
Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys
675 680 685
Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp
690 695 700
Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr
705 710 715 720
Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr
725 730 735
Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp
740 745 750
Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile
755 760 765
Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met
770 775 780
Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn
785 790 795 800
Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr
805 810 815
Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu
820 825 830
Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile
835 840 845
Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser Glu Ile Leu Asn Asn Ile
850 855 860
Ile Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu Ile Asp Leu Ser Gly
865 870 875 880
Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys
885 890 895
Asn Gln Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys Ile Arg Val Thr
900 905 910
Gln Asn Gln Asn Ile Ile Phe Asn Ser Val Phe Leu Asp Phe Ser Val
915 920 925
Ser Phe Trp Ile Arg Ile Pro Lys Tyr Lys Asn Asp Gly Ile Gln Asn
930 935 940
Tyr Ile His Asn Glu Tyr Thr Ile Ile Asn Cys Met Lys Asn Asn Ser
945 950 955 960
Gly Trp Lys Ile Ser Ile Arg Gly Asn Arg Ile Ile Trp Thr Leu Ile
965 970 975
Asp Ile Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn Ile Arg
980 985 990
Glu Asp Ile Ser Glu Tyr Ile Asn Arg Trp Phe Phe Val Thr Ile Thr
995 1000 1005
Asn Asn Leu Asn Asn Ala Lys Ile Tyr Ile Asn Gly Lys Leu Glu Ser
1010 1015 1020
Asn Thr Asp Ile Lys Asp Ile Arg Glu Val Ile Ala Asn Gly Glu Ile
1025 1030 1035 1040
Ile Phe Lys Leu Asp Gly Asp Ile Asp Arg Thr Gln Phe Ile Trp Met
1045 1050 1055
Lys Tyr Phe Ser Ile Phe Asn Thr Glu Leu Ser Gln Ser Asn Ile Glu
1060 1065 1070
Glu Arg Tyr Lys Ile Gln Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp
1075 1080 1085
Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly
1090 1095 1100
Asn Lys Asn Ser Tyr Ile Lys Leu Lys Lys Asp Ser Pro Val Gly Glu
1105 1110 1115 1120
Ile Leu Thr Arg Ser Lys Tyr Asn Gln Asn Ser Lys Tyr Ile Asn Tyr
1125 1130 1135
Arg Asp Leu Tyr Ile Gly Glu Lys Phe Ile Ile Arg Arg Lys Ser Asn
1140 1145 1150
Ser Gln Ser Ile Asn Asp Asp Ile Val Arg Lys Glu Asp Tyr Ile Tyr
1155 1160 1165
Leu Asp Phe Phe Asn Leu Asn Gln Glu Trp Arg Val Tyr Thr Tyr Lys
1170 1175 1180
Tyr Phe Lys Lys Glu Glu Glu Lys Leu Phe Leu Ala Pro Ile Ser Asp
1185 1190 1195 1200
Ser Asp Glu Phe Tyr Asn Thr Ile Gln Ile Lys Glu Tyr Asp Glu Gln
1205 1210 1215
Pro Thr Tyr Ser Cys Gln Leu Leu Phe Lys Lys Asp Glu Glu Ser Thr
1220 1225 1230
Asp Glu Ile Gly Leu Ile Gly Ile His Arg Phe Tyr Glu Ser Gly Ile
1235 1240 1245
Val Phe Glu Glu Tyr Lys Asp Tyr Phe Cys Ile Ser Lys Trp Tyr Leu
1250 1255 1260
Lys Glu Val Lys Arg Lys Pro Tyr Asn Leu Lys Leu Gly Cys Asn Trp
1265 1270 1275 1280
Gln Phe Ile Pro Lys Asp Glu Gly Trp Thr Glu
1285 1290
<210> 5
<211> 3843
<212> DNA
<213> 肉毒梭菌(Clostridium botulinum)
<400> 5
atgccaataa caattaacaa ctttaattat tcagatcctg ttgataataa aaatatttta 60
tatttagata ctcatttaaa tacattagct aatgagcctg aaaaagcctt tcgcattata 120
gggaatatat gggtaatacc cgatagattt tcaagagatt ctaatccaaa tttaaataaa 180
cctcctcgag ttacaagccc taaaagtggt tattatgatc ctaattattt gagtactgat 240
tctgaaaaag atacattttt aaaagaaatt ataaagttat ttaaaagaat taactctaga 300
gaaataggag aagaattaat atatagactt gcaacagaca taccctttcc tgggaataac 360
aatactccaa ttaatacttt tgattttgat gtagatttta acagtgttga tgttaaaact 420
agacaaggta acaactgggt taaaactggt agtataaatc ctagtgttat aataactgga 480
cctagagaaa acattataga cccagaaact tctacgttta aattaactaa caatactttt 540
gcggcacaag aaggatttgg tgctttatca ataatttcaa tatcacctag atttatgcta 600
acatatagta atgcaactaa taatgtagga gagggtagat tttctaagtc tgaattttgc 660
atggatccaa tactaatttt aatgcatgaa cttaatcatg caatgcataa tttatatgga 720
atagctatac caaatgatca aagaatttca tctgtaacta gtaatatttt ttattctcaa 780
tataaggtga aattagagta tgcagaaata tatgcatttg gaggtccaac tatagacctt 840
attcctaaaa gtgcaaggaa atattttgag gaaaaggcat tggattatta tagatccata 900
gctaaaagac ttaatagtat aactactgca aatccttcaa gctttaataa atatatagga 960
gaatataaac agaaacttat tagaaagtat agattcgtag tagaatcttc aggtgaagtt 1020
gcagtagatc gtaataagtt tgctgagtta tataaagaac ttacacaaat atttacagaa 1080
tttaactacg ctaaaatata taatgtacaa aataggaaaa tatatctttc aaatgtatat 1140
actccggtta cggcaaatat attagacgat aatgtttatg atatacaaaa tggatttaac 1200
atacctaaaa gtaatttaaa tgtactattt atgggtcaaa atttatctcg aaatccagca 1260
ttaagaaaag tcaatcctga aaatatgctt tatttattta caaaattttg ccataaagca 1320
atagatggta gatcattata taataaaaca ttagattgta gagagctttt agttaaaaat 1380
actgacttac cctttatagg tgatattagt gatatcaaaa ctgatatatt tttaagcaaa 1440
gatattaatg aagaaactga agttatagac tatccggaca atgtttcagt ggatcaagtt 1500
attctcagta agaatacctc agaacatgga caactagatt tattataccc tattattgaa 1560
ggtgagagtc aagtattacc gggagagaat caagtctttt atgataatag aactcaaaat 1620
gttgattatt tgaattctta ttattaccta gaatctcaaa aactaagtga taatgttgaa 1680
gattttactt ttacgacatc aattgaggaa gctttggata atagtggaaa agtatatact 1740
tactttccta aactagctga taaagtaaat acgggtgttc aaggtggttt atttttaatg 1800
tgggcaaatg atgtagttga agattttact acaaatattc taagaaaaga tacattagat 1860
aaaatatcag atgtatcagc tattattccc tatataggac ctgcattaaa tataagtaat 1920
tctgtaagaa ggggaaattt tactgaagca tttgcagtta ccggtgtaac tattttatta 1980
gaagcgtttc aagaatttac aatacctgca cttggtgcat ttgtgattta tagtaaggtt 2040
caagaaagaa acgagattat taaaactata gataattgtt tagaacaaag gattaaaaga 2100
tggaaagatt catatgaatg gatgatagga acgtggttat ccaggattac tactcaattt 2160
aataatataa gttatcaaat gtatgattct ttaaattatc aggcagatgc aatcaaagat 2220
aaaatagatt tagaatataa aaaatactca ggaagtgata aagaaaatat aaaaagtcaa 2280
gttgaaaatt taaaaaatag tttagatata aaaatctcgg aagcaatgaa taatataaat 2340
aaatttatac gagaatgttc tgtaacatac ttatttaaaa atatgctccc taaagtaatt 2400
gatgaattaa ataagtttga tttaaaaact aaaacagaat taattaatct tatagatagt 2460
cataatatta ttctagttgg tgaagtagat agattaaaag caaaagtaaa tgagagtttt 2520
gaaaatacaa taccctttaa tattttttca tatactaata attctttatt aaaagatata 2580
attaatgaat atttcaatag tattaatgat tcaaaaattt tgagcttaca aaacaaaaaa 2640
aatgctttag tggatacatc aggatataat gcagaagtga ggctagaagg tgatgttcaa 2700
gttaatacga tatatacaaa tgattttaaa ttaagtagtt caggagataa aattatagta 2760
aatttaaata ataatatttt atatagcgct atttatgaga actctagtgt tagtttttgg 2820
attaagatat ctaaagattt aactaattct cataatgaat atacaataat taatagtata 2880
aaacaaaatt ctgggtggaa attatgtatt aggaatggca atatagaatg gattttacaa 2940
gatattaata gaaagtataa aagtttaatt tttgattata gtgaatcatt aagtcataca 3000
ggatatacaa ataaatggtt ttttgttact ataactaata atataatggg gtatatgaaa 3060
ctttatataa atggagaatt aaagcagagt gaaagaattg aagatttaaa tgaggttaag 3120
ttagataaaa ccatagtatt tggaatagat gagaatatag atgagaatca gatgctttgg 3180
attagagatt ttaatatttt ttctaaagaa ttaagcaatg aagatattaa tattgtatat 3240
gagggacaaa tattaagaaa tgttattaaa gattattggg gaaatccttt gaagtttgat 3300
acagaatatt atattattaa tgataattat atagataggt atatagcacc taaaagtaat 3360
atacttgtac ttgttcagta tccagataga tctaaattat atactggaaa tcctattact 3420
attaaatcag tatctgataa gaatccttat agtagaattt taaatggaga taatataatg 3480
tttcatatgt tatataatag tgggaaatat atgataataa gagatactga tacaatatat 3540
gcaatagaag gaagagagtg ttcaaaaaat tgtgtatatg cattaaaatt acagagtaat 3600
ttaggtaatt atggtatagg tatatttagt ataaaaaata ttgtatctca aaataaatat 3660
tgtagtcaaa ttttctctag ttttatgaaa aatacaatgc ttctagcaga tatatataaa 3720
ccttggagat tttcttttga aaatgcatac acgccagttg cagtaactaa ttatgagaca 3780
aaactattat caacttcatc tttttggaaa tttatttcta gggatccagg atgggtagag 3840
taa 3843
<210> 6
<211> 1280
<212> PRT
<213> 肉毒梭菌(Clostridium botulinum)
<400> 6
Met Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn
1 5 10 15
Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu
20 25 30
Pro Glu Lys Ala Phe Arg Ile Ile Gly Asn Ile Trp Val Ile Pro Asp
35 40 45
Arg Phe Ser Arg Asp Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val
50 55 60
Thr Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp
65 70 75 80
Ser Glu Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg
85 90 95
Ile Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ala Thr
100 105 110
Asp Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp
115 120 125
Phe Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn
130 135 140
Asn Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly
145 150 155 160
Pro Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr
165 170 175
Asn Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile
180 185 190
Ser Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asn
195 200 205
Val Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile
210 215 220
Leu Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly
225 230 235 240
Ile Ala Ile Pro Asn Asp Gln Arg Ile Ser Ser Val Thr Ser Asn Ile
245 250 255
Phe Tyr Ser Gln Tyr Lys Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala
260 265 270
Phe Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr
275 280 285
Phe Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu
290 295 300
Asn Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly
305 310 315 320
Glu Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser
325 330 335
Ser Gly Glu Val Ala Val Asp Arg Asn Lys Phe Ala Glu Leu Tyr Lys
340 345 350
Glu Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn
355 360 365
Val Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr
370 375 380
Ala Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn
385 390 395 400
Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser
405 410 415
Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu
420 425 430
Phe Thr Lys Phe Cys His Lys Ala Ile Asp Gly Arg Ser Leu Tyr Asn
435 440 445
Lys Thr Leu Asp Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro
450 455 460
Phe Ile Gly Asp Ile Ser Asp Ile Lys Thr Asp Ile Phe Leu Ser Lys
465 470 475 480
Asp Ile Asn Glu Glu Thr Glu Val Ile Asp Tyr Pro Asp Asn Val Ser
485 490 495
Val Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu
500 505 510
Asp Leu Leu Tyr Pro Ile Ile Glu Gly Glu Ser Gln Val Leu Pro Gly
515 520 525
Glu Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu
530 535 540
Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu
545 550 555 560
Asp Phe Thr Phe Thr Thr Ser Ile Glu Glu Ala Leu Asp Asn Ser Gly
565 570 575
Lys Val Tyr Thr Tyr Phe Pro Lys Leu Ala Asp Lys Val Asn Thr Gly
580 585 590
Val Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp
595 600 605
Phe Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp
610 615 620
Val Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn
625 630 635 640
Ser Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val
645 650 655
Thr Ile Leu Leu Glu Ala Phe Gln Glu Phe Thr Ile Pro Ala Leu Gly
660 665 670
Ala Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys
675 680 685
Thr Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser
690 695 700
Tyr Glu Trp Met Ile Gly Thr Trp Leu Ser Arg Ile Thr Thr Gln Phe
705 710 715 720
Asn Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Asp
725 730 735
Ala Ile Lys Asp Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser
740 745 750
Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu
755 760 765
Asp Ile Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg
770 775 780
Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile
785 790 795 800
Asp Glu Leu Asn Lys Phe Asp Leu Lys Thr Lys Thr Glu Leu Ile Asn
805 810 815
Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu
820 825 830
Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Ile Pro Phe Asn Ile
835 840 845
Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr
850 855 860
Phe Asn Ser Ile Asn Asp Ser Lys Ile Leu Ser Leu Gln Asn Lys Lys
865 870 875 880
Asn Ala Leu Val Asp Thr Ser Gly Tyr Asn Ala Glu Val Arg Leu Glu
885 890 895
Gly Asp Val Gln Val Asn Thr Ile Tyr Thr Asn Asp Phe Lys Leu Ser
900 905 910
Ser Ser Gly Asp Lys Ile Ile Val Asn Leu Asn Asn Asn Ile Leu Tyr
915 920 925
Ser Ala Ile Tyr Glu Asn Ser Ser Val Ser Phe Trp Ile Lys Ile Ser
930 935 940
Lys Asp Leu Thr Asn Ser His Asn Glu Tyr Thr Ile Ile Asn Ser Ile
945 950 955 960
Lys Gln Asn Ser Gly Trp Lys Leu Cys Ile Arg Asn Gly Asn Ile Glu
965 970 975
Trp Ile Leu Gln Asp Ile Asn Arg Lys Tyr Lys Ser Leu Ile Phe Asp
980 985 990
Tyr Ser Glu Ser Leu Ser His Thr Gly Tyr Thr Asn Lys Trp Phe Phe
995 1000 1005
Val Thr Ile Thr Asn Asn Ile Met Gly Tyr Met Lys Leu Tyr Ile Asn
1010 1015 1020
Gly Glu Leu Lys Gln Ser Glu Arg Ile Glu Asp Leu Asn Glu Val Lys
1025 1030 1035 1040
Leu Asp Lys Thr Ile Val Phe Gly Ile Asp Glu Asn Ile Asp Glu Asn
1045 1050 1055
Gln Met Leu Trp Ile Arg Asp Phe Asn Ile Phe Ser Lys Glu Leu Ser
1060 1065 1070
Asn Glu Asp Ile Asn Ile Val Tyr Glu Gly Gln Ile Leu Arg Asn Val
1075 1080 1085
Ile Lys Asp Tyr Trp Gly Asn Pro Leu Lys Phe Asp Thr Glu Tyr Tyr
1090 1095 1100
Ile Ile Asn Asp Asn Tyr Ile Asp Arg Tyr Ile Ala Pro Lys Ser Asn
1105 1110 1115 1120
Ile Leu Val Leu Val Gln Tyr Pro Asp Arg Ser Lys Leu Tyr Thr Gly
1125 1130 1135
Asn Pro Ile Thr Ile Lys Ser Val Ser Asp Lys Asn Pro Tyr Ser Arg
1140 1145 1150
Ile Leu Asn Gly Asp Asn Ile Met Phe His Met Leu Tyr Asn Ser Gly
1155 1160 1165
Lys Tyr Met Ile Ile Arg Asp Thr Asp Thr Ile Tyr Ala Ile Glu Gly
1170 1175 1180
Arg Glu Cys Ser Lys Asn Cys Val Tyr Ala Leu Lys Leu Gln Ser Asn
1185 1190 1195 1200
Leu Gly Asn Tyr Gly Ile Gly Ile Phe Ser Ile Lys Asn Ile Val Ser
1205 1210 1215
Gln Asn Lys Tyr Cys Ser Gln Ile Phe Ser Ser Phe Met Lys Asn Thr
1220 1225 1230
Met Leu Leu Ala Asp Ile Tyr Lys Pro Trp Arg Phe Ser Phe Glu Asn
1235 1240 1245
Ala Tyr Thr Pro Val Ala Val Thr Asn Tyr Glu Thr Lys Leu Leu Ser
1250 1255 1260
Thr Ser Ser Phe Trp Lys Phe Ile Ser Arg Asp Pro Gly Trp Val Glu
1265 1270 1275 1280
<210> 7
<211> 3858
<212> DNA
<213> 肉毒梭菌(Clostridium botulinum)
<400> 7
atgacatggc cagtaaaaga ttttaattat agtgatcctg ttaatgacaa tgatatatta 60
tatttaagaa taccacaaaa taagttaatt actacacctg taaaagcttt tatgattact 120
caaaatattt gggtaatacc agaaagattt tcatcagata ctaatccaag tttaagtaaa 180
ccgcctagac ctacttcaaa gtatcaaagt tattatgatc ctagttattt atctactgat 240
gagcaaaaag atacattttt aaaagggatt ataaaattat ttaaaagaat taatgaaaga 300
gatataggaa aaaaattaat aaattattta gtagttggtt caccttttat gggagattca 360
agtacgcctg aagatacatt tgattttaca cgtcatacta ctaatattgc agttgaaaag 420
tttgaaaatg gtagttggaa agtaacaaat attataacac caagtgtatt gatatttgga 480
ccacttccta atatattaga ctatacagca tcccttacat tgcaaggaca acaatcaaat 540
ccatcatttg aagggtttgg aacattatct atactaaaag tagcacctga atttttgtta 600
acatttagtg atgtaacatc taatcaaagt tcagctgtat taggcaaatc tatattttgt 660
atggatccag taatagcttt aatgcatgag ttaacacatt ctttgcatca attgtatgga 720
ataaatatac catctgataa aaggattcgt ccacaagtta gcgagggatt tttttctcaa 780
gatggaccca acgtacaatt tgaggaatta tacacatttg gaggatcaga tgttgaaata 840
atacctcaaa ttgaaagatt acaattaaga gaaaaagcat taggtcacta taaagatata 900
gcgaaaagac ttaataatat taataaaact attccttcta gttggagtag taatatagat 960
aaatataaaa aaatattttc tgaaaagtat aattttgata aagataatac aggaaatttt 1020
gttgtaaata ttgataaatt caatagctta tattcagact tgactaatgt tatgtcagaa 1080
gttgtttatt cttcgcaata taatgttaaa aacaggactc attatttttc aaagcattat 1140
ctacctgtat ttgcaaatat attagatgat aatatttata ctataataaa cggttttaat 1200
ttaacaacta aaggttttaa tatagaaaat tcgggtcaga atatagaaag gaatcctgca 1260
ctacaaaaac ttagttcaga aagtgtagta gatttgttta caaaagtatg tttaagatta 1320
acaagaaata gtagagatga ttcaacatgt attcaagtta aaaataatac attaccttat 1380
gtagctgata aagatagcat ttcacaagaa atatttgaaa gtcaaattat tacagatgag 1440
actaatgtag aaaattattc agataatttt tcattagatg aatctatttt agatgcaaaa 1500
gtccctacta atcctgaagc agtagatcca ctgttaccca atgttaatat ggaaccttta 1560
aatgttccag gtgaagaaga agtattttat gatgatatta ctaaagatgt tgattattta 1620
aactcttatt attatttgga agcccaaaaa ttaagtaata atgttgaaaa tattactctt 1680
acaacttcag ttgaagaagc attaggttat agcaataaga tatacacatt tttacctagc 1740
ttagctgaaa aagtgaataa aggtgttcaa gcaggtttat tcttaaattg ggcgaatgaa 1800
gtagttgagg attttactac aaatattatg aaaaaagata cattggataa aatatcagat 1860
gtatcagcca taattccata tataggacct gccttaaata taggaaattc agcattaagg 1920
ggaaacttta agcaagcatt tgcaacagct ggtgtagctt ttttgttaga aggatttcca 1980
gagtttacaa tacctgcact cggtgtattt accttttata gttctattca agaaagagag 2040
aaaattatta aaactataga aaattgttta gaacaaagag ttaagagatg gaaagattca 2100
tatcaatgga tggtatcaaa ttggttgtca agaattacta ctcgatttaa tcatataagt 2160
tatcaaatgt atgattcttt gagttatcag gcagatgcaa tcaaagctaa aatagattta 2220
gaatataaaa aatactcagg aagtgataaa gaaaatataa aaagtcaagt tgaaaattta 2280
aaaaatagtt tagatgtaaa aatctcggaa gcaatgaata atataaataa atttatacga 2340
gaatgttctg taacatactt atttaaaaat atgctcccta aagtaattga tgaattaaat 2400
aagtttgatt taaaaactaa aacagaatta attaatctta tagatagtca taatattatt 2460
ctagttggtg aagtagatag attaaaagca aaagtaaatg agagttttga aaatacaata 2520
ccctttaata ttttttcata tactaataat tctttattaa aagatatgat taatgaatat 2580
ttcaatagta ttaatgattc aaaaattttg agcttacaaa ataaaaaaaa tactttgatg 2640
gatacatcag gatataacgc agaagtgaga gtagaaggca atgttcagct taatccaata 2700
tttccatttg actttaaatt aggtagttca ggggatgata gaggtaaagt tatagtaacc 2760
cagaatgaaa atattgtata taatgctatg tatgaaagtt ttagtattag tttttggatt 2820
aggataaata aatgggtaag taatttacct ggatatacta taattgatag tgttaaaaat 2880
aactcaggtt ggagtatagg tattattagt aattttttag tgtttacttt aaaacaaaat 2940
gaaaatagtg aacaagatat aaactttagt tatgatatat caaagaatgc tgcgggatat 3000
aataaatggt tttttgtaac tattactacc aatatgatgg gaaatatgat gatttatata 3060
aatggaaaat taatagatac tataaaagtt aaagagttaa ctggaattaa ttttagcaaa 3120
actataacat ttcaaatgaa taaaattcca aatactggct taattacctc agattctgat 3180
aacatcaata tgtggataag ggatttttat atctttgcta aagaattaga tgataaagat 3240
attaatatat tatttaatag cttgcaatat actaatgttg taaaagatta ttggggaaat 3300
gatttaagat atgataaaga atattacatg attaacgtaa attatatgaa tagatatatg 3360
tctaaaaaag gcaatggaat tgtttttaat acacgtaaaa ataataatga cttcaatgaa 3420
ggatataaaa ttataataaa aagaattaga ggaaatacaa atgatactag agtacgagga 3480
gaaaatgtat tatattttaa tactacaatt gataacaaac aatatagttt aggtatgtat 3540
aaaccttcta gaaatctagg gactgattta gttccactag gtgcattgga tcaaccaatg 3600
gatgagatac gtaaatatgg ttcgtttata atacaaccat gcaatacttt tgattactat 3660
gcatcacaat tatttttgtc aagtaatgca acaacaaata ggcttggaat actatcaatt 3720
ggtagttata gtttcaaact tggagatgac tattggttta atcacgaata tttaattcct 3780
gttataaaaa tagagcatta tgcttcatta ttagaatcaa catcaactca ttgggttttt 3840
gtacctgcaa gtgaataa 3858
<210> 8
<211> 1285
<212> PRT
<213> 肉毒梭菌(Clostridium botulinum)
<400> 8
Met Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp
1 5 10 15
Asn Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr
20 25 30
Pro Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu
35 40 45
Arg Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro
50 55 60
Thr Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp
65 70 75 80
Glu Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg
85 90 95
Ile Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val
100 105 110
Gly Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp
115 120 125
Phe Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly
130 135 140
Ser Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly
145 150 155 160
Pro Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly
165 170 175
Gln Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu
180 185 190
Lys Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn
195 200 205
Gln Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val
210 215 220
Ile Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly
225 230 235 240
Ile Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly
245 250 255
Phe Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr
260 265 270
Phe Gly Gly Ser Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Leu Gln
275 280 285
Leu Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu
290 295 300
Asn Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ser Ser Asn Ile Asp
305 310 315 320
Lys Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn
325 330 335
Thr Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser
340 345 350
Asp Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn
355 360 365
Val Lys Asn Arg Thr His Tyr Phe Ser Lys His Tyr Leu Pro Val Phe
370 375 380
Ala Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Ile Asn Gly Phe Asn
385 390 395 400
Leu Thr Thr Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu
405 410 415
Arg Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu
420 425 430
Phe Thr Lys Val Cys Leu Arg Leu Thr Arg Asn Ser Arg Asp Asp Ser
435 440 445
Thr Cys Ile Gln Val Lys Asn Asn Thr Leu Pro Tyr Val Ala Asp Lys
450 455 460
Asp Ser Ile Ser Gln Glu Ile Phe Glu Ser Gln Ile Ile Thr Asp Glu
465 470 475 480
Thr Asn Val Glu Asn Tyr Ser Asp Asn Phe Ser Leu Asp Glu Ser Ile
485 490 495
Leu Asp Ala Lys Val Pro Thr Asn Pro Glu Ala Val Asp Pro Leu Leu
500 505 510
Pro Asn Val Asn Met Glu Pro Leu Asn Val Pro Gly Glu Glu Glu Val
515 520 525
Phe Tyr Asp Asp Ile Thr Lys Asp Val Asp Tyr Leu Asn Ser Tyr Tyr
530 535 540
Tyr Leu Glu Ala Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr Leu
545 550 555 560
Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr Thr
565 570 575
Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala Gly
580 585 590
Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr Asn
595 600 605
Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Ala Ile
610 615 620
Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu Arg
625 630 635 640
Gly Asn Phe Lys Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu Leu
645 650 655
Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr Phe
660 665 670
Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn
675 680 685
Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp Met
690 695 700
Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Arg Phe Asn His Ile Ser
705 710 715 720
Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys Ala
725 730 735
Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu Asn
740 745 750
Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys Ile
755 760 765
Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser Val
770 775 780
Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu Asn
785 790 795 800
Lys Phe Asp Leu Lys Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp Ser
805 810 815
His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys Val
820 825 830
Asn Glu Ser Phe Glu Asn Thr Ile Pro Phe Asn Ile Phe Ser Tyr Thr
835 840 845
Asn Asn Ser Leu Leu Lys Asp Met Ile Asn Glu Tyr Phe Asn Ser Ile
850 855 860
Asn Asp Ser Lys Ile Leu Ser Leu Gln Asn Lys Lys Asn Thr Leu Met
865 870 875 880
Asp Thr Ser Gly Tyr Asn Ala Glu Val Arg Val Glu Gly Asn Val Gln
885 890 895
Leu Asn Pro Ile Phe Pro Phe Asp Phe Lys Leu Gly Ser Ser Gly Asp
900 905 910
Asp Arg Gly Lys Val Ile Val Thr Gln Asn Glu Asn Ile Val Tyr Asn
915 920 925
Ala Met Tyr Glu Ser Phe Ser Ile Ser Phe Trp Ile Arg Ile Asn Lys
930 935 940
Trp Val Ser Asn Leu Pro Gly Tyr Thr Ile Ile Asp Ser Val Lys Asn
945 950 955 960
Asn Ser Gly Trp Ser Ile Gly Ile Ile Ser Asn Phe Leu Val Phe Thr
965 970 975
Leu Lys Gln Asn Glu Asn Ser Glu Gln Asp Ile Asn Phe Ser Tyr Asp
980 985 990
Ile Ser Lys Asn Ala Ala Gly Tyr Asn Lys Trp Phe Phe Val Thr Ile
995 1000 1005
Thr Thr Asn Met Met Gly Asn Met Met Ile Tyr Ile Asn Gly Lys Leu
1010 1015 1020
Ile Asp Thr Ile Lys Val Lys Glu Leu Thr Gly Ile Asn Phe Ser Lys
1025 1030 1035 1040
Thr Ile Thr Phe Gln Met Asn Lys Ile Pro Asn Thr Gly Leu Ile Thr
1045 1050 1055
Ser Asp Ser Asp Asn Ile Asn Met Trp Ile Arg Asp Phe Tyr Ile Phe
1060 1065 1070
Ala Lys Glu Leu Asp Asp Lys Asp Ile Asn Ile Leu Phe Asn Ser Leu
1075 1080 1085
Gln Tyr Thr Asn Val Val Lys Asp Tyr Trp Gly Asn Asp Leu Arg Tyr
1090 1095 1100
Asp Lys Glu Tyr Tyr Met Ile Asn Val Asn Tyr Met Asn Arg Tyr Met
1105 1110 1115 1120
Ser Lys Lys Gly Asn Gly Ile Val Phe Asn Thr Arg Lys Asn Asn Asn
1125 1130 1135
Asp Phe Asn Glu Gly Tyr Lys Ile Ile Ile Lys Arg Ile Arg Gly Asn
1140 1145 1150
Thr Asn Asp Thr Arg Val Arg Gly Glu Asn Val Leu Tyr Phe Asn Thr
1155 1160 1165
Thr Ile Asp Asn Lys Gln Tyr Ser Leu Gly Met Tyr Lys Pro Ser Arg
1170 1175 1180
Asn Leu Gly Thr Asp Leu Val Pro Leu Gly Ala Leu Asp Gln Pro Met
1185 1190 1195 1200
Asp Glu Ile Arg Lys Tyr Gly Ser Phe Ile Ile Gln Pro Cys Asn Thr
1205 1210 1215
Phe Asp Tyr Tyr Ala Ser Gln Leu Phe Leu Ser Ser Asn Ala Thr Thr
1220 1225 1230
Asn Arg Leu Gly Ile Leu Ser Ile Gly Ser Tyr Ser Phe Lys Leu Gly
1235 1240 1245
Asp Asp Tyr Trp Phe Asn His Glu Tyr Leu Ile Pro Val Ile Lys Ile
1250 1255 1260
Glu His Tyr Ala Ser Leu Leu Glu Ser Thr Ser Thr His Trp Val Phe
1265 1270 1275 1280
Val Pro Ala Ser Glu
1285
<210> 9
<211> 3756
<212> DNA
<213> 肉毒梭菌(Clostridium botulinum)
<400> 9
atgccaaaaa ttaatagttt taattataat gatcctgtta atgatagaac aattttatat 60
attaaaccag gcggttgtca agaattttat aaatcattta atattatgaa aaatatttgg 120
ataattccag agagaaatgt aattggtaca accccccaag attttcatcc gcctacttca 180
ttaaaaaatg gagatagtag ttattatgac cctaattatt tacaaagtga tgaagaaaag 240
gatagatttt taaaaatagt cacaaaaata tttaatagaa taaataataa tctttcagga 300
gggattttat tagaagaact gtcaaaagct aatccatatt tagggaatga taatactcca 360
gataatcaat tccatattgg tgatgcatca gcagttgaga ttaaattctc aaatggtagc 420
caagacatac tattacctaa tgttattata atgggagcag agcctgattt atttgaaact 480
aacagttcca atatttctct aagaaataat tatatgccaa gcaatcaccg ttttggatca 540
atagctatag taacattctc acctgaatat tcttttagat ttaatgataa ttgtatgaat 600
gaatttattc aagatcctgc tcttacatta atgcatgaat taatacattc attacatgga 660
ctatatgggg ctaaagggat tactacaaag tatactataa cacaaaaaca aaatccccta 720
ataacaaata taagaggtac aaatattgaa gaattcttaa cttttggagg tactgattta 780
aacattatta ctagtgctca gtccaatgat atctatacta atcttctagc tgattataaa 840
aaaatagcgt ctaaacttag caaagtacaa gtatctaatc cactacttaa tccttataaa 900
gatgtttttg aagcaaagta tggattagat aaagatgcta gcggaattta ttcggtaaat 960
ataaacaaat ttaatgatat ttttaaaaaa ttatacagct ttacggaatt tgatttacga 1020
actaaatttc aagttaaatg taggcaaact tatattggac agtataaata cttcaaactt 1080
tcaaacttgt taaatgattc tatttataat atatcagaag gctataatat aaataattta 1140
aaggtaaatt ttagaggaca gaatgcaaat ttaaatccta gaattattac accaattaca 1200
ggtagaggac tagtaaaaaa aatcattaga ttttgtaaaa atattgtttc tgtaaaaggc 1260
ataaggaaat caatatgtat cgaaataaat aatggtgagt tattttttgt ggcttccgag 1320
aatagttata atgatgataa tataaatact cctaaagaaa ttgacgatac agtaacttca 1380
aataataatt atgaaaatga tttagatcag gttattttaa attttaatag tgaatcagca 1440
cctggacttt cagatgaaaa attaaattta actatccaaa atgatgctta tataccaaaa 1500
tatgattcta atggaacaag tgatatagaa caacatgatg ttaatgaact taatgtattt 1560
ttctatttag atgcacagaa agtgcccgaa ggtgaaaata atgtcaatct cacctcttca 1620
attgatacag cattattaga acaacctaaa atatatacat ttttttcatc agaatttatt 1680
aataatgtca ataaacctgt gcaagcagca ttatttgtaa gctggataca acaagtgtta 1740
gtagatttta ctactgaagc taaccaaaaa agtactgttg ataaaattgc agatatttct 1800
atagttgttc catatatagg tcttgcttta aatataggaa atgaagcaca aaaaggaaat 1860
tttaaagatg cacttgaatt attaggagca ggtattttat tagaatttga acccgagctt 1920
ttaattccta caattttagt attcacgata aaatcttttt taggttcatc tgataataaa 1980
aataaagtta ttaaagcaat aaataatgca ttgaaagaaa gagatgaaaa atggaaagaa 2040
gtatatagtt ttatagtatc gaattggatg actaaaatta atacacaatt taataaaaga 2100
aaagaacaaa tgtatcaagc tttacaaaat caagtaaatg caattaaaac aataatagaa 2160
tctaagtata atagttatac tttagaggaa aaaaatgagc ttacaaataa atatgatatt 2220
aagcaaatag aaaatgaact taatcaaaag gtttctatag caatgaataa tatagacagg 2280
ttcttaactg aaagttctat atcctattta atgaaaataa taaatgaagt aaaaattaat 2340
aaattaagag aatatgatga gaatgtcaaa acgtatttat tgaattatat tatacaacat 2400
ggatcaatct tgggagagag tcagcaagaa ctaaattcta tggtaactga taccctaaat 2460
aatagtattc cttttaagct ttcttcttat acagatgata aaattttaat ttcatatttt 2520
aataaattct ttaagagaat taaaagtagt tcagttttaa atatgagata taaaaatgat 2580
aaatacgtag atacttcagg atatgattca aatataaata ttaatggaga tgtatataaa 2640
tatccaacta ataaaaatca atttggaata tataatgata aacttagtga agttaatata 2700
tctcaaaatg attacattat atatgataat aaatataaaa attttagtat tagtttttgg 2760
gtaagaattc ctaactatga taataagata gtaaatgtta ataatgaata cactataata 2820
aattgtatga gagataataa ttcaggatgg aaagtatctc ttaatcataa tgaaataatt 2880
tggacattcg aagataatcg aggaattaat caaaaattag catttaacta tggtaacgca 2940
aatggtattt ctgattatat aaataagtgg atttttgtaa ctataactaa tgatagatta 3000
ggagattcta aactttatat taatggaaat ttaatagatc aaaaatcaat tttaaattta 3060
ggtaatattc atgttagtga caatatatta tttaaaatag ttaattgtag ttatacaaga 3120
tatattggta ttagatattt taatattttt gataaagaat tagatgaaac agaaattcaa 3180
actttatata gcaatgaacc taatacaaat attttgaagg atttttgggg aaattatttg 3240
ctttatgaca aagaatacta tttattaaat gtgttaaaac caaataactt tattgatagg 3300
agaaaagatt ctactttaag cattaataat ataagaagca ctattctttt agctaataga 3360
ttatatagtg gaataaaagt taaaatacaa agagttaata atagtagtac taacgataat 3420
cttgttagaa agaatgatca ggtatatatt aattttgtag ccagcaaaac tcacttattt 3480
ccattatatg ctgatacagc taccacaaat aaagagaaaa caataaaaat atcatcatct 3540
ggcaatagat ttaatcaagt agtagttatg aattcagtag gaaattgtac aatgaatttt 3600
aaaaataata atggaaataa tattgggttg ttaggtttca aggcagatac tgtcgttgct 3660
agtacttggt attatacaca tatgagagat catacaaaca gcaatggatg tttttggaac 3720
tttatttctg aagaacatgg atggcaagaa aaataa 3756
<210> 10
<211> 1251
<212> PRT
<213> 肉毒梭菌(Clostridium botulinum)
<400> 10
Met Pro Lys Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg
1 5 10 15
Thr Ile Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe Tyr Lys Ser
20 25 30
Phe Asn Ile Met Lys Asn Ile Trp Ile Ile Pro Glu Arg Asn Val Ile
35 40 45
Gly Thr Thr Pro Gln Asp Phe His Pro Pro Thr Ser Leu Lys Asn Gly
50 55 60
Asp Ser Ser Tyr Tyr Asp Pro Asn Tyr Leu Gln Ser Asp Glu Glu Lys
65 70 75 80
Asp Arg Phe Leu Lys Ile Val Thr Lys Ile Phe Asn Arg Ile Asn Asn
85 90 95
Asn Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu Ser Lys Ala Asn Pro
100 105 110
Tyr Leu Gly Asn Asp Asn Thr Pro Asp Asn Gln Phe His Ile Gly Asp
115 120 125
Ala Ser Ala Val Glu Ile Lys Phe Ser Asn Gly Ser Gln Asp Ile Leu
130 135 140
Leu Pro Asn Val Ile Ile Met Gly Ala Glu Pro Asp Leu Phe Glu Thr
145 150 155 160
Asn Ser Ser Asn Ile Ser Leu Arg Asn Asn Tyr Met Pro Ser Asn His
165 170 175
Arg Phe Gly Ser Ile Ala Ile Val Thr Phe Ser Pro Glu Tyr Ser Phe
180 185 190
Arg Phe Asn Asp Asn Cys Met Asn Glu Phe Ile Gln Asp Pro Ala Leu
195 200 205
Thr Leu Met His Glu Leu Ile His Ser Leu His Gly Leu Tyr Gly Ala
210 215 220
Lys Gly Ile Thr Thr Lys Tyr Thr Ile Thr Gln Lys Gln Asn Pro Leu
225 230 235 240
Ile Thr Asn Ile Arg Gly Thr Asn Ile Glu Glu Phe Leu Thr Phe Gly
245 250 255
Gly Thr Asp Leu Asn Ile Ile Thr Ser Ala Gln Ser Asn Asp Ile Tyr
260 265 270
Thr Asn Leu Leu Ala Asp Tyr Lys Lys Ile Ala Ser Lys Leu Ser Lys
275 280 285
Val Gln Val Ser Asn Pro Leu Leu Asn Pro Tyr Lys Asp Val Phe Glu
290 295 300
Ala Lys Tyr Gly Leu Asp Lys Asp Ala Ser Gly Ile Tyr Ser Val Asn
305 310 315 320
Ile Asn Lys Phe Asn Asp Ile Phe Lys Lys Leu Tyr Ser Phe Thr Glu
325 330 335
Phe Asp Leu Arg Thr Lys Phe Gln Val Lys Cys Arg Gln Thr Tyr Ile
340 345 350
Gly Gln Tyr Lys Tyr Phe Lys Leu Ser Asn Leu Leu Asn Asp Ser Ile
355 360 365
Tyr Asn Ile Ser Glu Gly Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe
370 375 380
Arg Gly Gln Asn Ala Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr
385 390 395 400
Gly Arg Gly Leu Val Lys Lys Ile Ile Arg Phe Cys Lys Asn Ile Val
405 410 415
Ser Val Lys Gly Ile Arg Lys Ser Ile Cys Ile Glu Ile Asn Asn Gly
420 425 430
Glu Leu Phe Phe Val Ala Ser Glu Asn Ser Tyr Asn Asp Asp Asn Ile
435 440 445
Asn Thr Pro Lys Glu Ile Asp Asp Thr Val Thr Ser Asn Asn Asn Tyr
450 455 460
Glu Asn Asp Leu Asp Gln Val Ile Leu Asn Phe Asn Ser Glu Ser Ala
465 470 475 480
Pro Gly Leu Ser Asp Glu Lys Leu Asn Leu Thr Ile Gln Asn Asp Ala
485 490 495
Tyr Ile Pro Lys Tyr Asp Ser Asn Gly Thr Ser Asp Ile Glu Gln His
500 505 510
Asp Val Asn Glu Leu Asn Val Phe Phe Tyr Leu Asp Ala Gln Lys Val
515 520 525
Pro Glu Gly Glu Asn Asn Val Asn Leu Thr Ser Ser Ile Asp Thr Ala
530 535 540
Leu Leu Glu Gln Pro Lys Ile Tyr Thr Phe Phe Ser Ser Glu Phe Ile
545 550 555 560
Asn Asn Val Asn Lys Pro Val Gln Ala Ala Leu Phe Val Ser Trp Ile
565 570 575
Gln Gln Val Leu Val Asp Phe Thr Thr Glu Ala Asn Gln Lys Ser Thr
580 585 590
Val Asp Lys Ile Ala Asp Ile Ser Ile Val Val Pro Tyr Ile Gly Leu
595 600 605
Ala Leu Asn Ile Gly Asn Glu Ala Gln Lys Gly Asn Phe Lys Asp Ala
610 615 620
Leu Glu Leu Leu Gly Ala Gly Ile Leu Leu Glu Phe Glu Pro Glu Leu
625 630 635 640
Leu Ile Pro Thr Ile Leu Val Phe Thr Ile Lys Ser Phe Leu Gly Ser
645 650 655
Ser Asp Asn Lys Asn Lys Val Ile Lys Ala Ile Asn Asn Ala Leu Lys
660 665 670
Glu Arg Asp Glu Lys Trp Lys Glu Val Tyr Ser Phe Ile Val Ser Asn
675 680 685
Trp Met Thr Lys Ile Asn Thr Gln Phe Asn Lys Arg Lys Glu Gln Met
690 695 700
Tyr Gln Ala Leu Gln Asn Gln Val Asn Ala Ile Lys Thr Ile Ile Glu
705 710 715 720
Ser Lys Tyr Asn Ser Tyr Thr Leu Glu Glu Lys Asn Glu Leu Thr Asn
725 730 735
Lys Tyr Asp Ile Lys Gln Ile Glu Asn Glu Leu Asn Gln Lys Val Ser
740 745 750
Ile Ala Met Asn Asn Ile Asp Arg Phe Leu Thr Glu Ser Ser Ile Ser
755 760 765
Tyr Leu Met Lys Ile Ile Asn Glu Val Lys Ile Asn Lys Leu Arg Glu
770 775 780
Tyr Asp Glu Asn Val Lys Thr Tyr Leu Leu Asn Tyr Ile Ile Gln His
785 790 795 800
Gly Ser Ile Leu Gly Glu Ser Gln Gln Glu Leu Asn Ser Met Val Thr
805 810 815
Asp Thr Leu Asn Asn Ser Ile Pro Phe Lys Leu Ser Ser Tyr Thr Asp
820 825 830
Asp Lys Ile Leu Ile Ser Tyr Phe Asn Lys Phe Phe Lys Arg Ile Lys
835 840 845
Ser Ser Ser Val Leu Asn Met Arg Tyr Lys Asn Asp Lys Tyr Val Asp
850 855 860
Thr Ser Gly Tyr Asp Ser Asn Ile Asn Ile Asn Gly Asp Val Tyr Lys
865 870 875 880
Tyr Pro Thr Asn Lys Asn Gln Phe Gly Ile Tyr Asn Asp Lys Leu Ser
885 890 895
Glu Val Asn Ile Ser Gln Asn Asp Tyr Ile Ile Tyr Asp Asn Lys Tyr
900 905 910
Lys Asn Phe Ser Ile Ser Phe Trp Val Arg Ile Pro Asn Tyr Asp Asn
915 920 925
Lys Ile Val Asn Val Asn Asn Glu Tyr Thr Ile Ile Asn Cys Met Arg
930 935 940
Asp Asn Asn Ser Gly Trp Lys Val Ser Leu Asn His Asn Glu Ile Ile
945 950 955 960
Trp Thr Phe Glu Asp Asn Arg Gly Ile Asn Gln Lys Leu Ala Phe Asn
965 970 975
Tyr Gly Asn Ala Asn Gly Ile Ser Asp Tyr Ile Asn Lys Trp Ile Phe
980 985 990
Val Thr Ile Thr Asn Asp Arg Leu Gly Asp Ser Lys Leu Tyr Ile Asn
995 1000 1005
Gly Asn Leu Ile Asp Gln Lys Ser Ile Leu Asn Leu Gly Asn Ile His
1010 1015 1020
Val Ser Asp Asn Ile Leu Phe Lys Ile Val Asn Cys Ser Tyr Thr Arg
1025 1030 1035 1040
Tyr Ile Gly Ile Arg Tyr Phe Asn Ile Phe Asp Lys Glu Leu Asp Glu
1045 1050 1055
Thr Glu Ile Gln Thr Leu Tyr Ser Asn Glu Pro Asn Thr Asn Ile Leu
1060 1065 1070
Lys Asp Phe Trp Gly Asn Tyr Leu Leu Tyr Asp Lys Glu Tyr Tyr Leu
1075 1080 1085
Leu Asn Val Leu Lys Pro Asn Asn Phe Ile Asp Arg Arg Lys Asp Ser
1090 1095 1100
Thr Leu Ser Ile Asn Asn Ile Arg Ser Thr Ile Leu Leu Ala Asn Arg
1105 1110 1115 1120
Leu Tyr Ser Gly Ile Lys Val Lys Ile Gln Arg Val Asn Asn Ser Ser
1125 1130 1135
Thr Asn Asp Asn Leu Val Arg Lys Asn Asp Gln Val Tyr Ile Asn Phe
1140 1145 1150
Val Ala Ser Lys Thr His Leu Phe Pro Leu Tyr Ala Asp Thr Ala Thr
1155 1160 1165
Thr Asn Lys Glu Lys Thr Ile Lys Ile Ser Ser Ser Gly Asn Arg Phe
1170 1175 1180
Asn Gln Val Val Val Met Asn Ser Val Gly Asn Cys Thr Met Asn Phe
1185 1190 1195 1200
Lys Asn Asn Asn Gly Asn Asn Ile Gly Leu Leu Gly Phe Lys Ala Asp
1205 1210 1215
Thr Val Val Ala Ser Thr Trp Tyr Tyr Thr His Met Arg Asp His Thr
1220 1225 1230
Asn Ser Asn Gly Cys Phe Trp Asn Phe Ile Ser Glu Glu His Gly Trp
1235 1240 1245
Gln Glu Lys
1250
<210> 11
<211> 3843
<212> DNA
<213> 肉毒梭菌(Clostridium botulinum)
<400> 11
atgccagttg taataaatag ttttaattat aatgaccctg ttaatgatga gacaatttta 60
tacatgcaga aaccatatga agaaagaagt agaaaatatt ataaagcttt tgagattatg 120
cctaatgttt ggataatgcc tgagagagat acaataggaa ctaagcctga tgagtttcag 180
gtgccggatt cattaaagaa cggaagtagt gcttattatg atcctaatta tttaaccact 240
gatgctgaaa aagatagata tttaaaaaca atgataaaat tatttaatag aattaatagt 300
aatcctacag ggaaagtttt gttagaagaa gtatcaaatg ctagaccata tttaggagat 360
gatgacacgc taattaatga attccttcca gttaatgtaa ctacaagtgt taatataaaa 420
ttttcaactg atgttgaaag ttcaataata tcgaatcttc ttgtattggg agcaggacct 480
gatatattta aagcttactg tacccccctt gtaaggttta ataagtcaga taaattaatt 540
gaaccaagta atcatggttt tggatcaatt aatatcttga cattttcacc tgagtatgaa 600
catattttta atgatattag tggagggaat cataatagta cagaatcatt tattgcagat 660
cctgcaattt cactagctca tgaattgata catgcactac atggattata cggggctaag 720
gcagttactc ataaagagtc tctagtagca gagcgaggac ctcttatgat agccgaaaag 780
cccataaggc tagaagaatt tttaactttt ggaggtgagg atttaaatat cattcctagt 840
gctatgaagg aaaaaatata taacgatctt ttagctaact atgaaaaaat agctactaga 900
cttagagaag ttaatacggc tcctcctgga tatgatatta atgaatataa agattatttt 960
caatggaagt atggactaga tagaaatgca gatggaagtt atactgtgaa tagaaataaa 1020
tttaatgaaa tttataaaaa attatatagc tttacagaga ttgacttagc aaataaattt 1080
aaagtaaaat gtagaaatac ttattttatt aaatatggat ttgtaaaagt tccaaatttg 1140
ttagatgatg atatttatac tgtatcagag gggtttaata taggtaattt agcagtaaac 1200
aatcgcggac aaaatataaa tttaaatcct aaaattattg attccattcc agataaaggt 1260
ttagtggaaa agattattaa attttgtaag agcattattc ctagaaaagg tacgaagcag 1320
tcaccgtcac tatgcattag agtaaataat agggagttat tttttgtagc ttcagaaagt 1380
agctataatg aaagtgatat taatacacct aaagaaattg acgatacaac aaatctaaat 1440
aataattata gaaataattt agatgaagtt attttagatt ataatagtga gacaatacct 1500
caaatatcaa atcgaacatt aaatacactt gtacaagaca atagttatgt gccaagatat 1560
gattctaatg gaacaagtga aatagaggaa tatgatgttg ttgactttaa tgtatttttc 1620
tatttacatg cacaaaaagt accagaaggt gaaaccaata taagtttaac ttcttcaatt 1680
gatacagcat tattagaaga atccaaagta tatacatttt tttcttcaga gtttatcgat 1740
actatcaata aacctgtaaa tgcagcacta tttatagatt ggataagcaa agtaataaga 1800
gattttacca ctgaagctac acaaaaaagt actgttgata agattgcaga catatcttta 1860
attgtaccct atgtaggtct tgctttgaat atagttattg aggcagaaaa aggaaatttt 1920
gaggaggcat ttgaattatt aggagcgggt attttattag aatttgtgcc agagcttaca 1980
attcctgtaa ttttagtgtt tacgataaaa tcctatatag attcatatga gaataaaaat 2040
aaagcaatta aagcaataaa taattcatta atcgaaagag aagcaaagtg gaaagaaata 2100
tatagttgga tagtatcaaa ttggcttact agaattaata cgcaatttaa taaaagaaaa 2160
gagcaaatgt atcaggcttt acaaaatcaa gtagatgcaa taaaaacagc aatagaatat 2220
aaatataata attatacttc agatgagaaa aatagacttg aatctaaata taatatcaat 2280
aatatagaag aagaattgaa taaaaaagtt tctttagcaa tgaaaaatat agaaagattt 2340
atgacagaaa gttctatatc ttatttaatg aaattaataa atgaagccga agttggtaaa 2400
ttaaaagaat atgataaaca tgttaagagc gatttattag actatattct ctaccataaa 2460
ttaatcttag gagagcagac aaaggaatta attgatttgg tgactagtac tttgaatagt 2520
agtattccat ttgaactttc ttcatatact aatgataaaa ttctaattat atattttaat 2580
agattatata aaaaaattaa agatagttct attttagata tgcgatatga aaataataaa 2640
tttatagata tctctggata tggttcaaat ataagcatta atggaaacgt atatatttat 2700
tcaacaaata gaaatcaatt tggaatatat agtggtaggc ttagtgaagt taatatagct 2760
caaaataatg atattatata caatagtaga tatcaaaatt ttagtattag tttctgggta 2820
accattccta aacactacag acctatgaat cgtaatcggg aatacactat aataaattgt 2880
atggggaata ataattcggg atggaaaata tcacttagaa ctattagaga ttgtgaaata 2940
atttggactt tacaagatac ttccggaaat aaggaaaaat taatttttag gtatgaagaa 3000
cttgctagta tatctgatta tataaataaa tggatttttg taactattac taataataga 3060
ttaggcaatt ctagaattta catcaatgga aatttaatag ttgaaaaatc aatttcgaat 3120
ttaggtgata ttcatgttag tgataatata ttatttaaaa ttgttggttg tgatgatgaa 3180
acgtatgttg gtataagata ttttaaagtt tttaatacgg aattagataa aacagaaatt 3240
gagactttat atagtaatga gccagatcca agtatcttaa aagactattg gggaaattat 3300
ttgctatata ataaaaaata ttatttattc aatttactaa gaaaagataa gtatattact 3360
cggaattcag gcattttaaa tattaatcaa caaagaggtg ttactggagg catatctgtt 3420
tttttgaact ataaattata tgaaggagta gaagttatta taagaaaaaa tgctcctata 3480
gatatatcta atacagataa ttttgttaga aaaaacgatc tagcatacat taatgtagta 3540
gatcatggtg tagaatatcg gttatatgct gatatatcaa ttacaaaatc agagaaaata 3600
ataaaattaa taagaacatc taatccaaac gatagcttag gtcaaattat agttatggat 3660
tcaataggaa ataattgcac aatgaatttt caaaacaatg atgggagcaa tataggatta 3720
ctaggttttc attcagatga tttggttgct agtagttggt attataacca tatacgaaga 3780
aacactagca gtaatggatg cttttggagt tttatttcta aagagcatgg ttggaaagaa 3840
taa 3843
<210> 12
<211> 1280
<212> PRT
<213> 肉毒梭菌(Clostridium botulinum)
<400> 12
Met Pro Val Val Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp
1 5 10 15
Glu Thr Ile Leu Tyr Met Gln Lys Pro Tyr Glu Glu Arg Ser Arg Lys
20 25 30
Tyr Tyr Lys Ala Phe Glu Ile Met Pro Asn Val Trp Ile Met Pro Glu
35 40 45
Arg Asp Thr Ile Gly Thr Lys Pro Asp Glu Phe Gln Val Pro Asp Ser
50 55 60
Leu Lys Asn Gly Ser Ser Ala Tyr Tyr Asp Pro Asn Tyr Leu Thr Thr
65 70 75 80
Asp Ala Glu Lys Asp Arg Tyr Leu Lys Thr Met Ile Lys Leu Phe Asn
85 90 95
Arg Ile Asn Ser Asn Pro Thr Gly Lys Val Leu Leu Glu Glu Val Ser
100 105 110
Asn Ala Arg Pro Tyr Leu Gly Asp Asp Asp Thr Leu Ile Asn Glu Phe
115 120 125
Leu Pro Val Asn Val Thr Thr Ser Val Asn Ile Lys Phe Ser Thr Asp
130 135 140
Val Glu Ser Ser Ile Ile Ser Asn Leu Leu Val Leu Gly Ala Gly Pro
145 150 155 160
Asp Ile Phe Lys Ala Tyr Cys Thr Pro Leu Val Arg Phe Asn Lys Ser
165 170 175
Asp Lys Leu Ile Glu Pro Ser Asn His Gly Phe Gly Ser Ile Asn Ile
180 185 190
Leu Thr Phe Ser Pro Glu Tyr Glu His Ile Phe Asn Asp Ile Ser Gly
195 200 205
Gly Asn His Asn Ser Thr Glu Ser Phe Ile Ala Asp Pro Ala Ile Ser
210 215 220
Leu Ala His Glu Leu Ile His Ala Leu His Gly Leu Tyr Gly Ala Lys
225 230 235 240
Ala Val Thr His Lys Glu Ser Leu Val Ala Glu Arg Gly Pro Leu Met
245 250 255
Ile Ala Glu Lys Pro Ile Arg Leu Glu Glu Phe Leu Thr Phe Gly Gly
260 265 270
Glu Asp Leu Asn Ile Ile Pro Ser Ala Met Lys Glu Lys Ile Tyr Asn
275 280 285
Asp Leu Leu Ala Asn Tyr Glu Lys Ile Ala Thr Arg Leu Arg Glu Val
290 295 300
Asn Thr Ala Pro Pro Gly Tyr Asp Ile Asn Glu Tyr Lys Asp Tyr Phe
305 310 315 320
Gln Trp Lys Tyr Gly Leu Asp Arg Asn Ala Asp Gly Ser Tyr Thr Val
325 330 335
Asn Arg Asn Lys Phe Asn Glu Ile Tyr Lys Lys Leu Tyr Ser Phe Thr
340 345 350
Glu Ile Asp Leu Ala Asn Lys Phe Lys Val Lys Cys Arg Asn Thr Tyr
355 360 365
Phe Ile Lys Tyr Gly Phe Val Lys Val Pro Asn Leu Leu Asp Asp Asp
370 375 380
Ile Tyr Thr Val Ser Glu Gly Phe Asn Ile Gly Asn Leu Ala Val Asn
385 390 395 400
Asn Arg Gly Gln Asn Ile Asn Leu Asn Pro Lys Ile Ile Asp Ser Ile
405 410 415
Pro Asp Lys Gly Leu Val Glu Lys Ile Ile Lys Phe Cys Lys Ser Ile
420 425 430
Ile Pro Arg Lys Gly Thr Lys Gln Ser Pro Ser Leu Cys Ile Arg Val
435 440 445
Asn Asn Arg Glu Leu Phe Phe Val Ala Ser Glu Ser Ser Tyr Asn Glu
450 455 460
Ser Asp Ile Asn Thr Pro Lys Glu Ile Asp Asp Thr Thr Asn Leu Asn
465 470 475 480
Asn Asn Tyr Arg Asn Asn Leu Asp Glu Val Ile Leu Asp Tyr Asn Ser
485 490 495
Glu Thr Ile Pro Gln Ile Ser Asn Arg Thr Leu Asn Thr Leu Val Gln
500 505 510
Asp Asn Ser Tyr Val Pro Arg Tyr Asp Ser Asn Gly Thr Ser Glu Ile
515 520 525
Glu Glu Tyr Asp Val Val Asp Phe Asn Val Phe Phe Tyr Leu His Ala
530 535 540
Gln Lys Val Pro Glu Gly Glu Thr Asn Ile Ser Leu Thr Ser Ser Ile
545 550 555 560
Asp Thr Ala Leu Leu Glu Glu Ser Lys Val Tyr Thr Phe Phe Ser Ser
565 570 575
Glu Phe Ile Asp Thr Ile Asn Lys Pro Val Asn Ala Ala Leu Phe Ile
580 585 590
Asp Trp Ile Ser Lys Val Ile Arg Asp Phe Thr Thr Glu Ala Thr Gln
595 600 605
Lys Ser Thr Val Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr
610 615 620
Val Gly Leu Ala Leu Asn Ile Val Ile Glu Ala Glu Lys Gly Asn Phe
625 630 635 640
Glu Glu Ala Phe Glu Leu Leu Gly Ala Gly Ile Leu Leu Glu Phe Val
645 650 655
Pro Glu Leu Thr Ile Pro Val Ile Leu Val Phe Thr Ile Lys Ser Tyr
660 665 670
Ile Asp Ser Tyr Glu Asn Lys Asn Lys Ala Ile Lys Ala Ile Asn Asn
675 680 685
Ser Leu Ile Glu Arg Glu Ala Lys Trp Lys Glu Ile Tyr Ser Trp Ile
690 695 700
Val Ser Asn Trp Leu Thr Arg Ile Asn Thr Gln Phe Asn Lys Arg Lys
705 710 715 720
Glu Gln Met Tyr Gln Ala Leu Gln Asn Gln Val Asp Ala Ile Lys Thr
725 730 735
Ala Ile Glu Tyr Lys Tyr Asn Asn Tyr Thr Ser Asp Glu Lys Asn Arg
740 745 750
Leu Glu Ser Lys Tyr Asn Ile Asn Asn Ile Glu Glu Glu Leu Asn Lys
755 760 765
Lys Val Ser Leu Ala Met Lys Asn Ile Glu Arg Phe Met Thr Glu Ser
770 775 780
Ser Ile Ser Tyr Leu Met Lys Leu Ile Asn Glu Ala Glu Val Gly Lys
785 790 795 800
Leu Lys Glu Tyr Asp Lys His Val Lys Ser Asp Leu Leu Asp Tyr Ile
805 810 815
Leu Tyr His Lys Leu Ile Leu Gly Glu Gln Thr Lys Glu Leu Ile Asp
820 825 830
Leu Val Thr Ser Thr Leu Asn Ser Ser Ile Pro Phe Glu Leu Ser Ser
835 840 845
Tyr Thr Asn Asp Lys Ile Leu Ile Ile Tyr Phe Asn Arg Leu Tyr Lys
850 855 860
Lys Ile Lys Asp Ser Ser Ile Leu Asp Met Arg Tyr Glu Asn Asn Lys
865 870 875 880
Phe Ile Asp Ile Ser Gly Tyr Gly Ser Asn Ile Ser Ile Asn Gly Asn
885 890 895
Val Tyr Ile Tyr Ser Thr Asn Arg Asn Gln Phe Gly Ile Tyr Ser Gly
900 905 910
Arg Leu Ser Glu Val Asn Ile Ala Gln Asn Asn Asp Ile Ile Tyr Asn
915 920 925
Ser Arg Tyr Gln Asn Phe Ser Ile Ser Phe Trp Val Thr Ile Pro Lys
930 935 940
His Tyr Arg Pro Met Asn Arg Asn Arg Glu Tyr Thr Ile Ile Asn Cys
945 950 955 960
Met Gly Asn Asn Asn Ser Gly Trp Lys Ile Ser Leu Arg Thr Ile Arg
965 970 975
Asp Cys Glu Ile Ile Trp Thr Leu Gln Asp Thr Ser Gly Asn Lys Glu
980 985 990
Lys Leu Ile Phe Arg Tyr Glu Glu Leu Ala Ser Ile Ser Asp Tyr Ile
995 1000 1005
Asn Lys Trp Ile Phe Val Thr Ile Thr Asn Asn Arg Leu Gly Asn Ser
1010 1015 1020
Arg Ile Tyr Ile Asn Gly Asn Leu Ile Val Glu Lys Ser Ile Ser Asn
1025 1030 1035 1040
Leu Gly Asp Ile His Val Ser Asp Asn Ile Leu Phe Lys Ile Val Gly
1045 1050 1055
Cys Asp Asp Glu Thr Tyr Val Gly Ile Arg Tyr Phe Lys Val Phe Asn
1060 1065 1070
Thr Glu Leu Asp Lys Thr Glu Ile Glu Thr Leu Tyr Ser Asn Glu Pro
1075 1080 1085
Asp Pro Ser Ile Leu Lys Asp Tyr Trp Gly Asn Tyr Leu Leu Tyr Asn
1090 1095 1100
Lys Lys Tyr Tyr Leu Phe Asn Leu Leu Arg Lys Asp Lys Tyr Ile Thr
1105 1110 1115 1120
Arg Asn Ser Gly Ile Leu Asn Ile Asn Gln Gln Arg Gly Val Thr Gly
1125 1130 1135
Gly Ile Ser Val Phe Leu Asn Tyr Lys Leu Tyr Glu Gly Val Glu Val
1140 1145 1150
Ile Ile Arg Lys Asn Ala Pro Ile Asp Ile Ser Asn Thr Asp Asn Phe
1155 1160 1165
Val Arg Lys Asn Asp Leu Ala Tyr Ile Asn Val Val Asp His Gly Val
1170 1175 1180
Glu Tyr Arg Leu Tyr Ala Asp Ile Ser Ile Thr Lys Ser Glu Lys Ile
1185 1190 1195 1200
Ile Lys Leu Ile Arg Thr Ser Asn Pro Asn Asp Ser Leu Gly Gln Ile
1205 1210 1215
Ile Val Met Asp Ser Ile Gly Asn Asn Cys Thr Met Asn Phe Gln Asn
1220 1225 1230
Asn Asp Gly Ser Asn Ile Gly Leu Leu Gly Phe His Ser Asp Asp Leu
1235 1240 1245
Val Ala Ser Ser Trp Tyr Tyr Asn His Ile Arg Arg Asn Thr Ser Ser
1250 1255 1260
Asn Gly Cys Phe Trp Ser Phe Ile Ser Lys Glu His Gly Trp Lys Glu
1265 1270 1275 1280
<210> 13
<211> 3894
<212> DNA
<213> 肉毒梭菌(Clostridium botulinum)
<223> “n为a、c、g或t”
<220>
<223> n为a、c、g或t
<220>
<221> misc_feature
<222> 20
<400> 13
atgccagtta atataaaaan ctttaattat aatgacccta ttaataatga tgacattatt 60
atgatggaac cattcaatga cccagggcca ggaacatatt ataaagcttt taggattata 120
gatcgtattt ggatagtacc agaaaggttt acttatggat ttcaacctga ccaatttaat 180
gccagtacag gagtttttag taaagatgtc tacgaatatt acgatccaac ttatttaaaa 240
accgatgctg aaaaagataa atttttaaaa acaatgatta aattatttaa tagaattaat 300
tcaaaaccat caggacagag attactggat atgatagtag atgctatacc ttatcttgga 360
aatgcatcta caccgcccga caaatttgca gcaaatgttg caaatgtatc tattaataaa 420
aaaattatcc aacctggagc tgaagatcaa ataaaaggtt taatgacaaa tttaataata 480
tttggaccag gaccagttct aagtgataat tttactgata gtatgattat gaatggccat 540
tccccaatat cagaaggatt tggtgcaaga atgatgataa gattttgtcc tagttgttta 600
aatgtattta ataatgttca ggaaaataaa gatacatcta tatttagtag acgcgcgtat 660
tttgcagatc cagctctaac gttaatgcat gaacttatac atgtgttaca tggattatat 720
ggaattaaga taagtaattt accaattact ccaaatacaa aagaattttt catgcaacat 780
agcgatcctg tacaagcaga agaactatat acattcggag gacatgatcc tagtgttata 840
agtccttcta cggatatgaa tatttataat aaagcgttac aaaattttca agatatagct 900
aataggctta atattgtttc aagtgcccaa gggagtggaa ttgatatttc cttatataaa 960
caaatatata aaaataaata tgattttgtt gaagatccta atggaaaata tagtgtagat 1020
aaggataagt ttgataaatt atataaggcc ttaatgtttg gctttactga aactaatcta 1080
gctggtgaat atggaataaa aactaggtat tcttatttta gtgaatattt gccaccgata 1140
aaaactgaaa aattgttaga caatacaatt tatactcaaa atgaaggctt taacatagct 1200
agtaaaaatc tcaaaacgga atttaatggt cagaataagg cggtaaataa agaggcttat 1260
gaagaaatca gcctagaaca tctcgttata tatagaatag caatgtgcaa gcctgtaatg 1320
tacaaaaata ccggtaaatc tgaacagtgt attattgtta ataatgagga tttatttttc 1380
atagctaata aagatagttt ttcaaaagat ttagctaaag cagaaactat agcatataat 1440
acacaaaata atactataga aaataatttt tctatagatc agttgatttt agataatgat 1500
ttaagcagtg gcatagactt accaaatgaa aacacagaac catttacaaa ttttgacgac 1560
atagatatcc ctgtgtatat taaacaatct gctttaaaaa aaatttttgt ggatggagat 1620
agcctttttg aatatttaca tgctcaaaca tttccttcta atatagaaaa tctacaacta 1680
acgaattcat taaatgatgc tttaagaaat aataataaag tctatacttt tttttctaca 1740
aaccttgttg aaaaagctaa tacagttgta ggtgcttcac tttttgtaaa ctgggtaaaa 1800
ggagtaatag atgattttac atctgaatcc acacaaaaaa gtactataga taaagtttca 1860
gatgtatcca taattattcc ctatatagga cctgctttga atgtaggaaa tgaaacagct 1920
aaagaaaatt ttaaaaatgc ttttgaaata ggtggagccg ctatcttaat ggagtttatt 1980
ccagaactta ttgtacctat agttggattt tttacattag aatcatatgt aggaaataaa 2040
gggcatatta ttatgacgat atccaatgct ttaaagaaaa gggatcaaaa atggacagat 2100
atgtatggtt tgatagtatc gcagtggctc tcaacggtta atactcaatt ttatacaata 2160
aaagaaagaa tgtacaatgc tttaaataat caatcacaag caatagaaaa aataatagaa 2220
gatcaatata atagatatag tgaagaagat aaaatgaata ttaacattga ttttaatgat 2280
atagatttta aacttaatca aagtataaat ttagcaataa acaatataga tgattttata 2340
aaccaatgtt ctatatcata tctaatgaat agaatgattc cattagctgt aaaaaagtta 2400
aaagactttg atgataatct taagagagat ttattggagt atatagatac aaatgaacta 2460
tatttacttg atgaagtaaa tattctaaaa tcaaaagtaa atagacacct aaaagacagt 2520
ataccatttg atctttcact atataccaag gacacaattt taatacaagt ttttaataat 2580
tatattagta atattagtag taatgctatt ttaagtttaa gttatagagg tgggcgttta 2640
atagattcat ctggatatgg tgcaactatg aatgtaggtt cagatgttat ctttaatgat 2700
ataggaaatg gtcaatttaa attaaataat tctgaaaata gtaatattac ggcacatcaa 2760
agtaaattcg ttgtatatga tagtatgttt gataatttta gcattaactt ttgggtaagg 2820
actcctaaat ataataataa tgatatacaa acttatcttc aaaatgagta tacaataatt 2880
agttgtataa aaaatgactc aggatggaaa gtatctatta agggaaatag aataatatgg 2940
acattaatag atgttaatgc aaaatctaaa tcaatatttt tcgaatatag tataaaagat 3000
aatatatcag attatataaa taaatggttt tccataacta ttactaatga tagattaggt 3060
aacgcaaata tttatataaa tggaagtttg aaaaaaagtg aaaaaatttt aaacttagat 3120
agaattaatt ctagtaatga tatagacttc aaattaatta attgtacaga tactactaaa 3180
tttgtttgga ttaaggattt taatattttt ggtagagaat taaatgctac agaagtatct 3240
tcactatatt ggattcaatc atctacaaat actttaaaag atttttgggg gaatccttta 3300
agatacgata cacaatacta tctgtttaat caaggtatgc aaaatatcta tataaagtat 3360
tttagtaaag cttctatggg ggaaactgca ccacgtacaa actttaataa tgcagcaata 3420
aattatcaaa atttatatct tggtttacga tttattataa aaaaagcatc aaattctcgg 3480
aatataaata atgataatat agtcagagaa ggagattata tatatcttaa tattgataat 3540
atttctgatg aatcttacag agtatatgtt ttggtgaatt ctaaagaaat tcaaactcaa 3600
ttatttttag cacccataaa tgatgatcct acgttctatg atgtactaca aataaaaaaa 3660
tattatgaaa aaacaacata taattgtcag atactttgcg aaaaagatac taaaacattt 3720
gggctgtttg gaattggtaa atttgttaaa gattatggat atgtttggga tacctatgat 3780
aattattttt gcataagtca gtggtatctc agaagaatat ctgaaaatat aaataaatta 3840
aggttgggat gtaattggca attcattccc gtggatgaag gatggacaga ataa 3894
<210> 14
<211> 1297
<212> PRT
<213> 肉毒梭菌(Clostridium botulinum)
<223> “Xaa可以是任何天然存在的氨基酸”
<220>
<223> Xaa可以是任何天然存在的氨基酸
<220>
<221> 不确定的
<222> 7
<400> 14
Met Pro Val Asn Ile Lys Xaa Phe Asn Tyr Asn Asp Pro Ile Asn Asn
1 5 10 15
Asp Asp Ile Ile Met Met Glu Pro Phe Asn Asp Pro Gly Pro Gly Thr
20 25 30
Tyr Tyr Lys Ala Phe Arg Ile Ile Asp Arg Ile Trp Ile Val Pro Glu
35 40 45
Arg Phe Thr Tyr Gly Phe Gln Pro Asp Gln Phe Asn Ala Ser Thr Gly
50 55 60
Val Phe Ser Lys Asp Val Tyr Glu Tyr Tyr Asp Pro Thr Tyr Leu Lys
65 70 75 80
Thr Asp Ala Glu Lys Asp Lys Phe Leu Lys Thr Met Ile Lys Leu Phe
85 90 95
Asn Arg Ile Asn Ser Lys Pro Ser Gly Gln Arg Leu Leu Asp Met Ile
100 105 110
Val Asp Ala Ile Pro Tyr Leu Gly Asn Ala Ser Thr Pro Pro Asp Lys
115 120 125
Phe Ala Ala Asn Val Ala Asn Val Ser Ile Asn Lys Lys Ile Ile Gln
130 135 140
Pro Gly Ala Glu Asp Gln Ile Lys Gly Leu Met Thr Asn Leu Ile Ile
145 150 155 160
Phe Gly Pro Gly Pro Val Leu Ser Asp Asn Phe Thr Asp Ser Met Ile
165 170 175
Met Asn Gly His Ser Pro Ile Ser Glu Gly Phe Gly Ala Arg Met Met
180 185 190
Ile Arg Phe Cys Pro Ser Cys Leu Asn Val Phe Asn Asn Val Gln Glu
195 200 205
Asn Lys Asp Thr Ser Ile Phe Ser Arg Arg Ala Tyr Phe Ala Asp Pro
210 215 220
Ala Leu Thr Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr
225 230 235 240
Gly Ile Lys Ile Ser Asn Leu Pro Ile Thr Pro Asn Thr Lys Glu Phe
245 250 255
Phe Met Gln His Ser Asp Pro Val Gln Ala Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly His Asp Pro Ser Val Ile Ser Pro Ser Thr Asp Met Asn Ile
275 280 285
Tyr Asn Lys Ala Leu Gln Asn Phe Gln Asp Ile Ala Asn Arg Leu Asn
290 295 300
Ile Val Ser Ser Ala Gln Gly Ser Gly Ile Asp Ile Ser Leu Tyr Lys
305 310 315 320
Gln Ile Tyr Lys Asn Lys Tyr Asp Phe Val Glu Asp Pro Asn Gly Lys
325 330 335
Tyr Ser Val Asp Lys Asp Lys Phe Asp Lys Leu Tyr Lys Ala Leu Met
340 345 350
Phe Gly Phe Thr Glu Thr Asn Leu Ala Gly Glu Tyr Gly Ile Lys Thr
355 360 365
Arg Tyr Ser Tyr Phe Ser Glu Tyr Leu Pro Pro Ile Lys Thr Glu Lys
370 375 380
Leu Leu Asp Asn Thr Ile Tyr Thr Gln Asn Glu Gly Phe Asn Ile Ala
385 390 395 400
Ser Lys Asn Leu Lys Thr Glu Phe Asn Gly Gln Asn Lys Ala Val Asn
405 410 415
Lys Glu Ala Tyr Glu Glu Ile Ser Leu Glu His Leu Val Ile Tyr Arg
420 425 430
Ile Ala Met Cys Lys Pro Val Met Tyr Lys Asn Thr Gly Lys Ser Glu
435 440 445
Gln Cys Ile Ile Val Asn Asn Glu Asp Leu Phe Phe Ile Ala Asn Lys
450 455 460
Asp Ser Phe Ser Lys Asp Leu Ala Lys Ala Glu Thr Ile Ala Tyr Asn
465 470 475 480
Thr Gln Asn Asn Thr Ile Glu Asn Asn Phe Ser Ile Asp Gln Leu Ile
485 490 495
Leu Asp Asn Asp Leu Ser Ser Gly Ile Asp Leu Pro Asn Glu Asn Thr
500 505 510
Glu Pro Phe Thr Asn Phe Asp Asp Ile Asp Ile Pro Val Tyr Ile Lys
515 520 525
Gln Ser Ala Leu Lys Lys Ile Phe Val Asp Gly Asp Ser Leu Phe Glu
530 535 540
Tyr Leu His Ala Gln Thr Phe Pro Ser Asn Ile Glu Asn Leu Gln Leu
545 550 555 560
Thr Asn Ser Leu Asn Asp Ala Leu Arg Asn Asn Asn Lys Val Tyr Thr
565 570 575
Phe Phe Ser Thr Asn Leu Val Glu Lys Ala Asn Thr Val Val Gly Ala
580 585 590
Ser Leu Phe Val Asn Trp Val Lys Gly Val Ile Asp Asp Phe Thr Ser
595 600 605
Glu Ser Thr Gln Lys Ser Thr Ile Asp Lys Val Ser Asp Val Ser Ile
610 615 620
Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Val Gly Asn Glu Thr Ala
625 630 635 640
Lys Glu Asn Phe Lys Asn Ala Phe Glu Ile Gly Gly Ala Ala Ile Leu
645 650 655
Met Glu Phe Ile Pro Glu Leu Ile Val Pro Ile Val Gly Phe Phe Thr
660 665 670
Leu Glu Ser Tyr Val Gly Asn Lys Gly His Ile Ile Met Thr Ile Ser
675 680 685
Asn Ala Leu Lys Lys Arg Asp Gln Lys Trp Thr Asp Met Tyr Gly Leu
690 695 700
Ile Val Ser Gln Trp Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile
705 710 715 720
Lys Glu Arg Met Tyr Asn Ala Leu Asn Asn Gln Ser Gln Ala Ile Glu
725 730 735
Lys Ile Ile Glu Asp Gln Tyr Asn Arg Tyr Ser Glu Glu Asp Lys Met
740 745 750
Asn Ile Asn Ile Asp Phe Asn Asp Ile Asp Phe Lys Leu Asn Gln Ser
755 760 765
Ile Asn Leu Ala Ile Asn Asn Ile Asp Asp Phe Ile Asn Gln Cys Ser
770 775 780
Ile Ser Tyr Leu Met Asn Arg Met Ile Pro Leu Ala Val Lys Lys Leu
785 790 795 800
Lys Asp Phe Asp Asp Asn Leu Lys Arg Asp Leu Leu Glu Tyr Ile Asp
805 810 815
Thr Asn Glu Leu Tyr Leu Leu Asp Glu Val Asn Ile Leu Lys Ser Lys
820 825 830
Val Asn Arg His Leu Lys Asp Ser Ile Pro Phe Asp Leu Ser Leu Tyr
835 840 845
Thr Lys Asp Thr Ile Leu Ile Gln Val Phe Asn Asn Tyr Ile Ser Asn
850 855 860
Ile Ser Ser Asn Ala Ile Leu Ser Leu Ser Tyr Arg Gly Gly Arg Leu
865 870 875 880
Ile Asp Ser Ser Gly Tyr Gly Ala Thr Met Asn Val Gly Ser Asp Val
885 890 895
Ile Phe Asn Asp Ile Gly Asn Gly Gln Phe Lys Leu Asn Asn Ser Glu
900 905 910
Asn Ser Asn Ile Thr Ala His Gln Ser Lys Phe Val Val Tyr Asp Ser
915 920 925
Met Phe Asp Asn Phe Ser Ile Asn Phe Trp Val Arg Thr Pro Lys Tyr
930 935 940
Asn Asn Asn Asp Ile Gln Thr Tyr Leu Gln Asn Glu Tyr Thr Ile Ile
945 950 955 960
Ser Cys Ile Lys Asn Asp Ser Gly Trp Lys Val Ser Ile Lys Gly Asn
965 970 975
Arg Ile Ile Trp Thr Leu Ile Asp Val Asn Ala Lys Ser Lys Ser Ile
980 985 990
Phe Phe Glu Tyr Ser Ile Lys Asp Asn Ile Ser Asp Tyr Ile Asn Lys
995 1000 1005
Trp Phe Ser Ile Thr Ile Thr Asn Asp Arg Leu Gly Asn Ala Asn Ile
1010 1015 1020
Tyr Ile Asn Gly Ser Leu Lys Lys Ser Glu Lys Ile Leu Asn Leu Asp
1025 1030 1035 1040
Arg Ile Asn Ser Ser Asn Asp Ile Asp Phe Lys Leu Ile Asn Cys Thr
1045 1050 1055
Asp Thr Thr Lys Phe Val Trp Ile Lys Asp Phe Asn Ile Phe Gly Arg
1060 1065 1070
Glu Leu Asn Ala Thr Glu Val Ser Ser Leu Tyr Trp Ile Gln Ser Ser
1075 1080 1085
Thr Asn Thr Leu Lys Asp Phe Trp Gly Asn Pro Leu Arg Tyr Asp Thr
1090 1095 1100
Gln Tyr Tyr Leu Phe Asn Gln Gly Met Gln Asn Ile Tyr Ile Lys Tyr
1105 1110 1115 1120
Phe Ser Lys Ala Ser Met Gly Glu Thr Ala Pro Arg Thr Asn Phe Asn
1125 1130 1135
Asn Ala Ala Ile Asn Tyr Gln Asn Leu Tyr Leu Gly Leu Arg Phe Ile
1140 1145 1150
Ile Lys Lys Ala Ser Asn Ser Arg Asn Ile Asn Asn Asp Asn Ile Val
1155 1160 1165
Arg Glu Gly Asp Tyr Ile Tyr Leu Asn Ile Asp Asn Ile Ser Asp Glu
1170 1175 1180
Ser Tyr Arg Val Tyr Val Leu Val Asn Ser Lys Glu Ile Gln Thr Gln
1185 1190 1195 1200
Leu Phe Leu Ala Pro Ile Asn Asp Asp Pro Thr Phe Tyr Asp Val Leu
1205 1210 1215
Gln Ile Lys Lys Tyr Tyr Glu Lys Thr Thr Tyr Asn Cys Gln Ile Leu
1220 1225 1230
Cys Glu Lys Asp Thr Lys Thr Phe Gly Leu Phe Gly Ile Gly Lys Phe
1235 1240 1245
Val Lys Asp Tyr Gly Tyr Val Trp Asp Thr Tyr Asp Asn Tyr Phe Cys
1250 1255 1260
Ile Ser Gln Trp Tyr Leu Arg Arg Ile Ser Glu Asn Ile Asn Lys Leu
1265 1270 1275 1280
Arg Leu Gly Cys Asn Trp Gln Phe Ile Pro Val Asp Glu Gly Trp Thr
1285 1290 1295
Glu

Claims (15)

1.一种用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒神经毒素,其中所述肉毒神经毒素通过注射到腮腺和颌下腺中施用,并且其中施用到所述腮腺中的每一个和所述颌下腺中的每一个中的肉毒神经毒素的剂量之间的比率介于1.45:1与1.7:1之间。
2.根据权利要求1所述的供使用的肉毒神经毒素,其中施用到腮腺和颌下腺中的所述肉毒神经毒素的总剂量介于70 U与110 U之间。
3.根据权利要求1或2中任一项所述的供使用的肉毒神经毒素,其中所述肉毒神经毒素在肉毒神经毒素浓度介于45 U/mL与55 U/mL之间的范围内的水性组合物中施用。
4.根据权利要求1到3中任一项所述的供使用的肉毒神经毒素,其中所述肉毒神经毒素以每一个注射部位0.3到0.5mL施用到所述颌下腺中并且以每一个注射部位0.5到0.7mL施用到所述腮腺中。
5.根据权利要求1到4中任一项所述的供使用的肉毒神经毒素,其中所述肉毒神经毒素注射到每一个颌下腺的一个部位中和/或注射到每一个腮腺的一个部位中。
6.根据权利要求1到5中任一项所述的供使用的肉毒神经毒素,其中通过使用超声引导或不使用超声引导将所述肉毒神经毒素注射到腮腺和颌下腺中。
7.根据权利要求1到6中任一项所述的供使用的肉毒神经毒素,其中以至少两个连续的治疗周期,优选地以至少2个、至少3个或至少4个治疗周期将所述肉毒神经毒素施用到腮腺和颌下腺中。
8.根据权利要求7所述的供使用的肉毒神经毒素,其中将所述肉毒神经毒素施用到腮腺和颌下腺中的两个连续治疗周期之间存在时间间隔,其中所述时间间隔介于10周与20周之间或介于12周与20周之间,具体地介于14周与18周之间,更具体地15周、16周或17周。
9.根据权利要求1到8中任一项所述的供使用的肉毒神经毒素,其中所述肉毒神经毒素是肉毒神经毒素复合物。
10.根据权利要求1到9中任一项所述的供使用的肉毒神经毒素,其中所述肉毒神经毒素是肉毒神经毒素复合物的神经毒性组分,其中所述神经毒性组分缺乏肉毒梭菌神经毒素复合物的任何其它蛋白质组分。
11.根据权利要求1到10中任一项所述的供使用的肉毒神经毒素,其中所述肉毒神经毒素选自包含以下的血清型的组:肉毒神经毒素血清型A、肉毒神经毒素血清型B、肉毒神经毒素血清型C1、肉毒神经毒素血清型D、肉毒神经毒素血清型E、肉毒神经毒素血清型F或肉毒神经毒素血清型G。
12.根据权利要求1到11中任一项所述的供使用的肉毒神经毒素,其中所述疾病或病状与帕金森病、进行性核上性麻痹、皮质基底节变性、多系统萎缩、肌萎缩侧索硬化症(ALS)、脑瘫、中风、创伤性脑损伤(TBI)、氯氮平诱导的多涎、瑞特综合征(Rett syndrome)、安格曼综合征(Angelman syndrome)、癫痫性脑病和脑肿瘤、全咽切除术(totalpharyngolaryngectomy)、环状软骨上喉切除术(supracricoidlaryngectomy)和声门上喉切除术、痴呆、或智力残疾相关。
13.根据权利要求12所述的供使用的肉毒神经毒素,其中所述疾病或病状与中风相关。
14.一种药物组合物,其包括用于治疗与流涎或唾液产生增多相关的疾病或病状的肉毒神经毒素和药学上可接受的载剂,其中所述肉毒神经毒素通过注射到腮腺和颌下腺中施用,并且其中施用到所述腮腺中的每一个和所述颌下腺中的每一个中的肉毒神经毒素的剂量之间的比率介于1.45:1与1.7:1之间。
15.一种治疗患者的与流涎或唾液产生增多相关的疾病或病状的方法,所述方法包括通过注射到腮腺和颌下腺中来施用治疗有效量的肉毒神经毒素,其中施用到所述腮腺中的每一个和所述颌下腺中的每一个中的肉毒神经毒素的量之间的比率介于1.45:1与1.7:1之间。
CN201880012061.6A 2017-03-24 2018-03-19 肉毒神经毒素在治疗流涎中的改进的用途 Pending CN110430892A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17162719 2017-03-24
EP17162719.3 2017-03-24
PCT/EP2018/056850 WO2018172264A1 (en) 2017-03-24 2018-03-19 Improved use of botulinum neurotoxin in the treatment of sialorrhea

Publications (1)

Publication Number Publication Date
CN110430892A true CN110430892A (zh) 2019-11-08

Family

ID=58412969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880012061.6A Pending CN110430892A (zh) 2017-03-24 2018-03-19 肉毒神经毒素在治疗流涎中的改进的用途

Country Status (12)

Country Link
US (3) US10709772B2 (zh)
EP (1) EP3600384A1 (zh)
JP (2) JP7007392B2 (zh)
KR (1) KR20190126794A (zh)
CN (1) CN110430892A (zh)
AU (1) AU2018237799A1 (zh)
BR (1) BR112019016585A2 (zh)
CA (1) CA3051785A1 (zh)
IL (2) IL268688B2 (zh)
MX (1) MX2019009860A (zh)
WO (1) WO2018172264A1 (zh)
ZA (1) ZA201904752B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3600384A1 (en) * 2017-03-24 2020-02-05 Merz Pharma GmbH & Co. KGaA Improved use of botulinum neurotoxin in the treatment of sialorrhea
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US10960061B1 (en) * 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010013494A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用
CN106163545A (zh) * 2013-12-12 2016-11-23 株式会社美得拓石 长效的新肉毒杆菌毒素配制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP2266600B1 (en) 2004-07-26 2014-09-10 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US20090142430A1 (en) * 2007-12-04 2009-06-04 Ira Sanders Methods for Preventing or Treating Complications of Airway Control Devices
AU2009223161B2 (en) 2008-03-14 2014-10-30 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101640694B1 (ko) 2011-09-29 2016-07-18 셀스냅, 엘엘씨 독소생산능 시험용 조성물 및 방법
US20180360995A1 (en) * 2012-04-02 2018-12-20 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
KR20140147950A (ko) 2013-06-20 2014-12-31 서울대학교산학협력단 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물
RU2704808C2 (ru) 2013-06-28 2019-10-31 Мерц Фарма Гмбх Энд Ко. Кгаа Средства и способы для определения биологической активности полипептидов нейротоксина в клетках
US10549042B2 (en) * 2014-12-23 2020-02-04 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled glass syringe
EP3600384A1 (en) * 2017-03-24 2020-02-05 Merz Pharma GmbH & Co. KGaA Improved use of botulinum neurotoxin in the treatment of sialorrhea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010013494A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用
CN106163545A (zh) * 2013-12-12 2016-11-23 株式会社美得拓石 长效的新肉毒杆菌毒素配制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B WILKEN等: "Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B", 《NEUROPEDIATRICS》 *
M ELLIES等: "Successful management of drooling with botulinum toxin A in neurologically disabled children", 《NEUROPEDIATRICS》 *
PIERANGELO BARBERO等: "Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia", 《J NEUROL》 *
李志进: "肉毒毒素A在涎腺疾病治疗中的应用进展", 《口腔医学研究》 *

Also Published As

Publication number Publication date
JP2020511428A (ja) 2020-04-16
US20190000938A1 (en) 2019-01-03
IL268688A (en) 2019-10-31
IL268688B1 (en) 2023-09-01
JP7007392B2 (ja) 2022-01-24
US20230270829A1 (en) 2023-08-31
WO2018172264A1 (en) 2018-09-27
MX2019009860A (es) 2019-10-15
US10709772B2 (en) 2020-07-14
AU2018237799A1 (en) 2019-08-08
BR112019016585A2 (pt) 2020-03-31
JP7495438B2 (ja) 2024-06-04
RU2019123259A3 (zh) 2021-06-24
JP2022058511A (ja) 2022-04-12
ZA201904752B (en) 2020-02-26
IL304733B2 (en) 2024-08-01
IL304733A (en) 2023-09-01
RU2019123259A (ru) 2021-04-26
CA3051785A1 (en) 2018-09-27
IL268688B2 (en) 2024-01-01
EP3600384A1 (en) 2020-02-05
US20200297823A1 (en) 2020-09-24
IL304733B1 (en) 2024-04-01
US11529398B2 (en) 2022-12-20
KR20190126794A (ko) 2019-11-12

Similar Documents

Publication Publication Date Title
CN110430892A (zh) 肉毒神经毒素在治疗流涎中的改进的用途
KR101818895B1 (ko) 생물학적 활성이 감소된 신경독
KR102606174B1 (ko) 트리플 가이드 서열을 지닌 crispr/cas9를 사용한 엑손 스키핑 변형을 위한 최적화된 전략
US20020107199A1 (en) Methods of administering botulinum toxin
US20020086036A1 (en) Methods for treating hyperhidrosis
KR101882461B1 (ko) 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도
KR20150000468A (ko) 단축된 생물학적 활성을 나타내는 신경독소
JP2015504304A (ja) ポリ−グリシンを伴う修飾神経毒及びその使用
KR20210130711A (ko) 진전의 치료를 위한 보툴리눔 신경독의 신규 용도
TW202140522A (zh) 上面部紋路之處理
CA3135835A1 (en) Topical formulations of recombinant collagens
KR20170121194A (ko) 세포 내로의 보툴리눔 신경독소의 특이적 흡수를 향상시키는 방법
WO2011160826A1 (en) Botulinum toxin therapy
KR102282266B1 (ko) 시험관내 시험 시스템에서의 보툴리눔 신경독소에 대한 세포의 감수성을 표준화 및 증가시키기 위한 갱글리오사이드
CN114269384A (zh) 调节肉毒杆菌神经毒素作用的组合物
RU2826569C2 (ru) Новые способы применения ботулинического нейротоксина для лечения тремора
CN118159284A (zh) 包含肉毒杆菌衍生肽的用于止痛的组合物
KR20230059121A (ko) 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물
RU2778481C2 (ru) Улучшенное применение ботулинического нейротоксина в лечении сиалореи
CN108070020B (zh) 一种抗衰老、加速细胞新陈代谢的化妆品组合物
CN116847873A (zh) 脑损伤治疗
JP2022502446A (ja) ボツリヌス神経毒血清型eの治療的及び美容的使用
KR20090063644A (ko) 단백질분해효소 및 이를 코딩하는 유전자

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010196

Country of ref document: HK